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ASSOCIATION OF POSTPRANDIAL DYSLIPIDEMIA 
AND HBA1c LEVELS WITH CAROTID INTIMA-
MEDIA THICKNESS IN PATIENTS WITH TYPE 2 
DIABETES MELLITUS 
 
ABSTRACT 
BACKGROUND 
Macrovascular disease is a significant cause of mortality in diabetic patients 
.The studies done in the past two decades or so have highlighted the role of  
augmented and prolonged dysmetabolism occurring in the postprandial state in 
type 2 diabetes mellitus,  hyperglycemia and dyslipidemia being the key 
players. Hypertriglyceridemia and low HDL cholesterol levels constitute the 
most common dyslipidemic pattern in type 2 diabetic patients. Postprandial 
lipid measurements provide a more meaningful insight regarding the lipemic 
status of a individual. HbA1c level is a reliable measurement of chronic 
hyperglycemia in a given patient. Thus postprandial dyslipidemia and 
hyperglycemia act as independent and cumulative factors in causing 
postprandial endothelial dysfunction.To look for the role of postprandial 
dyslipidemia, and hyperglycemia in accelerating atherosclerosis, we can thus 
examine the correlation between postprandial lipid levels as well as HbA1c 
levels with carotid IMT values in diabetic individuals. 
AIMS AND OBJECTIVES 
1. To assess the extent of influence of postprandial lipidemia and HbA1c 
levels on carotid intima media thickness in patients with type 2 
diabetes mellitus. 
2. To analyse the correlation of post prandial dyslipidemia and HbA1c 
levels with development of macrovascular complications in 
individuals with type 2 diabetes mellitus. 
3. To assess the usefulness of post prandial lipid profile estimation in all 
type 2 diabetes patients and to thus prevent the onset of progressive, 
accelerated atherosclerosis in a patient with type 2 diabetes mellitus. 
MATERIAL AND METHODS 
This is a cross sectional study in which 100 patients with type 2 diabetes 
mellitus in the age group of 35-65 years, with average duration of diabetes 
between one to six years were included. A standardized mixed meal was given 
to all the patients after an overnight fast. Blood samples were drawn before and 
4 hours after the standardized test meal. The HbA1c, fasting and postprandial 
lipid profile levels and glucose levels were estimated. Fasting and postprandial 
triglycerides, total Cholesterol, HDL, VLDL were measured by standard 
laboratory technique.The CIMT was measured by Doppler Ultrasonogram. 
Carotid Artery Doppler was done by B-mode ultrasound by using a 7.5 MHZ 
transducer  
RESULTS 
Age, duration since diagnosis, sex, mode of treatment, history of smoking, 
history of alcohol intake, BMI, history of systemic hypertension, the 
systolic and diastolic blood pressure values, both fasting and postprandial 
HDL, both fasting and postprandial LDL. 
The p value for the above parameters was not significant as noted earlier 
suggesting that all these variables did not influence the CIMT in a significant 
manner. 
The fasting and postprandial cholesterol, fasting and post prandial 
triglycerides, fasting and post prandial blood sugar values, the HbA1c 
values all correlated significantly with the CIMT values(p value<0.001) 
showing the influence of these parameters to the variation in CIMT and hence 
their atherogenic potential. 
Among the significant parameters, the postprandial Cholesterol, postprandial 
Triglycerides, fasting blood sugar and HbA1c were found to be significant in 
both univariate and multivariate regression analysis. Among these post prandial 
triglyceride level had the strongest influence on the CIMT values. 
CONCLUSION 
1. The Carotid intima media thickness is significantly increased in people 
with postprandial dyslipidemia (especially postprandial 
hypertriglyceridemia and postprandial hypercholesterolemia).Among the 
dyslipidemias,  postprandial triglycerides exert the strongest influence on 
the variation in the Carotid intima media thickness. 
2. The HbA1c levels also independently influence the Carotid intima media 
thickness. 
3. Chronic hyperglycemia and postprandial dyslipidemia both independently 
and cumulatively influence the Carotid intima media thickness. 
4. Chronic hyperglycemia and postprandial dyslipidemia can be labeled as 
independent predictor of accelerated atherosclerosis in individuals with 
type 2 Diabetes Mellitus. 
5. In diabetic individuals, postprandial lipid profile may be suggested to 
predict the future macrovascular complication of diabetes mellitus. 
6.  Hence suggested emphasis on post prandial lipid profile estimation in all 
diabetic individuals. 
KEY WORDS 
Diabetes, macrovascular, atherosclerosis, dyslipidemia, hyperglycemia, 
postprandial, HbA1c, Carotid Intima media thickness(CIMT). 
 
 
 
 
INTRODUCTION 
 
 
Diabetes mellitus (DM) comprises of a set of metabolic disorders that are 
characterized by hyperglycemia. (1) The prevalence of diabetes worldwide has 
increased extraordinarily over the last twenty years, from approximately 30 
million cases in the eighties to about 285 million as per the 2010 statistics. The 
International Diabetes Federation predicted that 438 million people will have 
DM by 2030.
(1) 
Macrovascular complications of diabetes mellitus include cardiovascular 
diseases, cerebrovascular accidents and peripheral vascular disease. 
Macrovascular disease is a significant cause of mortality in diabetic patients. 
Diabetic individuals have a multitude of risk factors for atherogenesis, and the 
odds of developing coronary artery disease and ischemic strokes are 2- to 4-
times and 2- to 3-times more, respectively, than non diabetic individuals. 
(2-5) 
 
The Framingham Heart Study demonstrated a markedly elevated incidence of 
Peripheral vascular disease, Congestive cardiac failure, ischemic heart disease, 
Acute coronary syndromes, and sudden cardiovascular death in persons with 
diabetes mellitus. Diabetes mellitus has been labeled as "CHD risk equivalent." 
by The American Heart Association 
(1) 
Patients with type 2 diabetes with no 
previous history of STEMI have identical  risk for acute coronary events 
compared to non diabetic individuals who have had previous history of 
Myocardial Infarction.
(1) 
 
Since the traditional risk factors cannot completely account for the increased 
coronary artery disease risk in diabetic patients, other potential  risk factors 
need to be sought for.
(6)
 Two key pathological mechanisms playing a major role 
in the development of atherosclerotic changes are vessel wall  inflammation and 
activation of coagulation.
 
 
The studies done in the past two decades or so have highlighted the role of  
augmented and prolonged dysmetabolism occurring in the postprandial state in 
type 2 diabetes mellitus..
(8)
 In the late 1970s, Zilversmit suggested that 
atherosclerosis is predominantly a postprandial phenomenon.
(9,10)
 Since then, a 
huge amount of evidence has been put forward consolidating a relationship 
between postprandial dysmetabolism and the macrovascular complications of 
diabetes, with hyperglycemia and dyslipidemia being the key players.
(11-14) 
 
Hypertriglyceridemia and low HDL cholesterol levels constitute the most 
common dyslipidemic pattern in type 2 diabetic patients. 
(15)
Traditionally we 
measure only the fasting lipid values. In fact these values represent the nadir of 
the lipid values over 24 hours.  Postprandial lipid measurements, especially 
triglyceride levels provide a more meaningful insight regarding the lipemic 
status of a individual. 
 The triglyceride levels in serum generally remain elevated for about 3 to 6 
hours after a meal. This postprandial hypertriglyceridemia (more than 2.72 
mmol/l or 201 mg/dl) is exacerbated by the next routine meal and thus the 
lipemic milieu persists throughout the day .Therefore, measuring and 
documenting postprandial dyslipidemia in diabetic patients is vital in addition to 
measuring the fasting lipid levels. 
(16-18) 
A prospective study by Koskinen P et al has revealed that hypertriglyceridemia 
is the most significant risk factor for coronary artery disease (CAD). In fact 
elevated triglyceride levels may be a harbinger of future IHD than high LDL 
cholesterol levels. 
(19)
 Hypertriglyceridemia (more than 1.7 mmol/l or 150 
mg/dl) often precedes hypercholesterolemia in diabetic patients with early-onset 
IHD. Acute coronary events occur more frequently in patients with fasting 
triglyceridemia (more than 1.13 mmol/l or100 mg/dl) 
(21) 
While fasting hypertriglyceridemia may be a potential risk factor for 
atherosclerosis, particularly in the presence of diabetes mellitus, this association 
has not been consistently strong. However, when TGs are studied in 
postprandial state, they emerge as stronger and independent coronary risk 
factor. 
(10)
 Postprandial dyslipidemia  has been linked with asymptomatic and 
symptomatic macrovascular disease in subjects with normal fasting values. The 
increased risk of atherosclerosis among them,  might therefore be related to the 
higher postprandial lipemia. 
 
It is hypothesized that elevated postprandial lipids levels may lead to an 
alteration in oxidative stress and consequent endothelial dysfunction that may 
finally lead to atherosclerosis and macrovascular disease in diabetic patients. 
(7, 
21, 22)
 Several mechanisms have been hypothesized to cause postprandial 
triglyceride abnormalities in type 2 diabetes subjects. There is significant delay 
in triglyceride clearance in diabetic patients, more so in individuals with 
macrovascular disease. 
Chronic hyperglycemia results in impaired endothelial function. Recent studies 
done in both healthy as well as type 2 diabetic individuals indicate that even 
acute hyperglycaemia can cause profound endothelial dysfunction. 
(23)
 The 
circulating ICAM-1 levels in plasma significantly increased, following an oral 
glucose tolerance test in diabetic and normal subjects which is an indirect 
indicator of endothelial cell activation. 
(24, 25) 
HbA1c level is a reliable 
measurement of chronic hyperglycemia in a given patient. A Chinese 
population based study done by Hung CS et al demonstrated that glycated 
haemoglobin levels have a significant correlation with carotid intima-media 
thickness. 
(26) 
 
Ceriello and co-workers demonstrated an additive effect of hypertriglyceridemia 
and hyperglycaemia in hampering endothelial function. A single metabolic 
component inadequately accounts for the real life postprandial dysmetabolic 
milieu. Thus postprandial dyslipidemia and hyperglycemia act as independent 
and cumulative factors in causing postprandial endothelial dysfunction. Hence 
both these values should be targeted by treatment protocols to prevent the 
development of macrovascular complications. 
(27) 
Measurement of the carotid intimal-medial thickness (CIMT)  by B mode 
ultrasonography has proved to be a safe, non invasive, quantitative  and easily 
repeatable method for assessing and documenting early onset  athero-sclerotic 
changes in vasculature.
(28-30)
 An increase in carotid intima media thickness is 
associated with a higher risk of cerebrovascular disease and Ischemic Heart 
Disease. To look for the role of postprandial dyslipidemia, and hyperglycemia 
in accelerating atherosclerosis, we can thus examine the correlation between 
postprandial lipid levels as well as HbA1c levels with carotid IMT values in 
diabetic individuals with no clinical, laboratory or imaging evidence of overt 
macrovascular disease. This study aims to highlight two major sets of 
biochemical parameters in diabetic individuals, which if properly controlled by 
drugs and diet modification, can prevent future comorbidities caused by diabetic 
macrovascular disease. 
 
 
AIMS AND OBJECTIVES 
1. To assess the extent of influence of postprandial lipidemia and HbA1c 
levels on carotid intima media thickness in patients with type 2 
diabetes mellitus. 
2. To analyse the correlation of post prandial dyslipidemia and HbA1c 
levels with development of macrovascular complications in 
individuals with type 2 diabetes mellitus. 
3. To assess the usefulness of post prandial lipid profile estimation in all 
type 2 diabetes patients and to thus prevent the onset of progressive, 
accelerated atherosclerosis in a patient with type 2 diabetes mellitus. 
 
 
 
 
 
 
 
 
 
 
 
 
LITERATURE REVIEW 
ATHEROSCLEROSIS 
It is a generic term which reflects arterial wall thickening and loss of elasticity. 
(33)
The term atherosclerosis was coined by Felix Marchand in 1904.
 
In 1908, atherosclerosis was experimentally induced by A.L.Ignatowski by 
feeding cholesterol rich food thereby demonstrating a relationship between 
dyslipidemia and atherosclerosis.
(35)
The first description of atherosclerosis in 
the modern era was given by Leonardo Da Vinci.
(7) 
PATHOGENESIS : 
The atheromatous lesions form in the intima and subsequently encroach upon 
the lumen. 
The various theories regarding the pathogenesis of atherosclerosis are 
(33) 
1. Humoral theory: (Karl Von Rokitansky) – highlights the role of thrombus 
formation and healing 
2. Cellular theory: (Rudolf Virchow) – highlights the role of cellular 
proliferation in the arterial intima subsequent to infiltration of intima by 
plasma components. 
3. The recent theories are “response -to- injury”(35) and “response-to-
retention” hypothesis.(36) 
The morphology can vary from fatty streaks which are the earliest lesions in 
the evolution of atherosclerosis to fibro-fatty plaques.
(33)
 The fibro-fatty 
plaques have three main components : cells including smooth muscle cells, T 
cells and macrophages ; extracellular matrix consisting of collagen, elastin 
and proteoglycans; and both intracellular and extracellular lipids. 
 
Beneath the superficial cap of smooth muscle cells and dense collagen, lies 
cellular area. The deeper region of the plaques contains a necrotic core, 
consisting of lipids, cell debris, foam cells and fibrin. The lumen of the 
affected arteries is narrowed as these plaques impinge on the arterial 
lumen.
(33) 
 
Fig 1: The Various Stages of 
Atherosclerotic Plaque 
Formation 
VULNERABLE PLAQUE: 
The concept of vulnerable plaque was proposed by Muller 
(38). It’s an 
atherosclerotic plaque with fibrous cap which is less than or equal to 65 
micrometer. It commonly occurs in proximal arteries. They have a lipid rich 
necrotic core and a thin fibrinous cap. These plaques are more vulnerable to 
rupture and therefore have higher propensity to cause thrombotic events. 
(37) 
 
Two key players responsible for the development of atherosclerosis are 
inflammation and activation of coagulation. 
(7)
 The primary pathology is the 
profound vascular endothelial dysfunction. The unique structural and functional 
properties of the endothelium, such as regulation of the vascular tone, vascular 
wall permeability, control of thrombogenesis and thrombolysis, and regulation 
of cell growth, collectively safeguard the vascular system. 
(21)
 The normal 
production, function and degradation of nitric oxide play a vital role in the 
majority of the above said processes. Endothelial functions cannot be measured 
directly. So several indirect methods have been postulated to estimate and 
quantify endothelial function. The assessment of plasma levels of endothelial-
cell derived proteins like von Willebrand’s factor (vWF), vascular cell adhesion 
molecule-1 (VCAM-1), inter cellular adhesion molecule-1 (ICAM-1) can be 
done to demonstrate endothelial activation. Measurement of nitric oxide-
dependent vasodilatation and measuring flow mediated dilatation (FMD) of the 
brachial artery by non-invasive ultrasound can also be done. Increased plasma 
concentrations of vWF, VCAM-1 and ICAM-1, and an impaired FMD have all 
been associated with an increased risk of cardiovascular disease. 
(21, 31)
 
 
LIPIDS AN OVERVIEW 
PLASMA LIPIDS 
Total plasma lipid is 400-600 mg/dl with roughly one third each of cholesterol, 
triglycerides and phospholipids. 
The lipids being insoluble in plasma, carriers are required for their transport in 
plasma and they are complexed with proteins to form lipoproteins. In the 
lipoprotein complex, the protein part is called apolipoprotein.
(32) 
LIPOPROTEINS – CLASSIFICATION
 
The plasma lipoproteins are divided into five major types as per density  either 
by ultracentrifuge method or by electrophoresis.
(39) 
1. Chylomicrons 
2. Very low density lipoproteins (VLDL) or pre-beta lipoproteins 
3. Intermediate density lipoproteins (IDL) or broad-beta lipoproteins 
4. Low density lipoproteins (lDL) or beta lipoproteins 
5. High density lipoproteins (HDL) or alpha lipoproteins 
 
 
APOLIPOPROTEINS 
In lipoproteins, the protein part is apolipoprotein or apoprotein
(32) 
Function of apolipoproteins 
1. Helps to solubilize lipids 
2. Form structural components of lipoproteins 
3. Enzyme activation eg. Apo C-II activates lipoprotein lipase 
4. Facilitates binding to specific receptors eg. Apo B-100 in LDL receptor 
binding 
 
LIPIDS- DIGESTION , TRANSPORT AND METABOLISM
(32)
 
Triacylglycerols, small amounts of cholesterol and phospholipids constitute the 
major lipids in day to day diet. The average Indian diet contains about 20 to 30 
grams lipids per day whereas Western diet contains two to three fold more 
quantity of lipids. 
Digestion of lipids 
After being emulsified by peristaltic movements, both lingual and gastric lipase 
help digest about 30% of dietary triglycerides. In intestine, pancreatic lipase 
with the help of co-lipase and bile salts, plays a major role in step by step 
hydrolysis of triglycerides. Cholesterol esters are hydrolysed to free cholesterol 
and fatty acids while action of Phospholipase A₂ enzyme produces 
lysophospholipid and a fatty acid. These products of digestion are are absorbed 
at the microvillous surface of the jejunal mucosa by the formation of micelles 
and about 98% of dietary lipids are absorbed.  
CHYLOMICRONS 
Within the intestinal cells, the fatty acids are resterified to form triglycerides. 
The intestinal cells convert glucose to glycerol phosphate and then add three 
activated fatty acid molecules to synthesize triglycerides. The triglycerides, 
cholesterol ester and phospholipids along with apo B-48 and apo-A  are 
incorporated to chylomicrons and are transported through lacteals into thoracic 
duct and  then into systemic circulation. Normally the postprandial lipemia 
clears within a few hours by uptake of chylomicrons by tissues. Later apo-A and 
apo-E are added on to chylomicrons. 
Chylomicrons are metabolized mainly in adipose tissue and skeletal muscles. 
The Lipoprotein lipase(LpL) enzyme which is present in the endothelial cells of 
capillaries of the adipose tissue , muscle and heart is activated by apolipoprotein 
C-II and the enzyme hydrolyses triglycerides in chylomicrons to fatty acids and 
glycerol.The fatty acids are utilised by the peripheral tissues and glycerol goes 
to the liver where it is reused. Insulin increases the LpL activity. The 
postprandial release of insulin thus favours fatty acid uptake and storage as 
triglycerides in adipose tissue. 
The chylomicron remnants with reduced triglycerides content and apo B-48 and 
apo E are taken up by liver cells by receptor mediated endocytosis and apo E 
helps in binding to the hepatic cell receptors. Chylomicrons are thus the 
transport form of dietary triglycerides to adipose tissue for storage and to the 
adipose tissue and heart for energy needs. 
VERY LOW DENSITY LIPOPROTEINS (VLDL) OR PRE-BETA 
LIPOPROTEINS 
Endogenous triglycerides are synthesized in the liver by esterification of 
fatty acyl CoA with either glycrol-3-phosphate or dihydroxy acetone 
phosphate (DHAP). VLDLs are the major carriers of endogenous 
triglycerides. The endogenous triglycerides are incorporated into VLDL 
along with hepatic cholesterol and apolipoproteins like apo B-100, apo C-II 
and apo E. The half life of VLDL is one to three hours. 
INTERMEDIATE DENSITY LIPOPROTEINS (IDL) OR BROAD-BETA 
LIPOPROTEINS 
When VLDL reaches peripheral tissues, lipoprotein lipase is activated by Apo C 
II
(40)
 . The LpL liberates fatty acids that are taken up by peripheral tissues. The 
remnant is called intermediate density lipoprotein and contains less of 
triglycerides and more of cholesterol as well as apo B-100 and apo E. The 
majority of IDL further loses triglyceride content and apo E and becomes LDL. 
The stepwise conversion of VLDL to IDL and then to LDL is called 
“Lipoprotein Cascade Pathway “. 
LOW DENSITY LIPOPROTEINS (LDL) OR BETALIPOPROTEINS 
These are cholesterol rich(with more than 75% of plasma cholesterol 
incorporated into LDL) containing only apo B-100. Most of LDL are derived 
from VLDL and small part directly released from liver. They have a half life of 
2 days in blood. The main function is transport of cholesterol from liver to the 
peripheral tissues. The LDL receptors are present in clathrin-coated pits. When 
apo B-II binds to these receptors, the receptor-LDL complex is internalized by 
endocytosis which binds to lysosomes. The apoproteins are degraded and the 
cholesterol esters are hydrolysed to free cholesterol. The free receptors return to 
the membrane to bind new LDL. 
The cholesterol thus taken up can be incorporated into cell membrane or used 
for hormone synthesis or re-esterified and stored with the help of  enzyme Acyl 
Cholesterol Acyl Transferace(ACAT) or be transported back to the liver with 
help of HDL. 
Since most of the LDL receptors are present on the hepatic cells, liver has a 
major role in determining the levels of LDL cholesterol.  
Lipoprotein (a), when present, is attached to apo B-100 by a disulphide bond. 
Due to its homology with plasminogens, it interferes with plasminogen 
activation and impairs fibrinolysis. Any person with lipoprotein (a) levels more 
than 30 mg/dl are more susceptible for thrombotic events. 
HIGH DENSITY LIPOPROTEINS(HDL) OR ALPHA LIPOPROTEINS 
 It is the major transport form of cholesterol from peripheral tissue to liver. 
HDL are synthesized by the intestinal cells and liver and release nascent HDL 
into blood. These are discoid in shape. On reaching the peripheral tissues, the 
apo A-1 of HDL activates LCAT (lecithin cholesterol acyl transferase) in 
plasma. LCAT binds to HDL disc and acts on lecithin present on the 
phospholipid bilayer of HDL. One molecule of PUFA attached to the second 
carbon atom of lecithin is removed to form lysolecithin and this PUFA is 
transferred to cholesterol to form cholesterol esters. The cholesterol ester moves 
into the HDL disc. The process is repeated and the HDL disc rich in cholesterol 
esters is then called mature HDL. These reach the liver and are taken up by liver 
with help of apo-A1 mediated receptor mechanism. Hepatic lipase hydrolyses 
the HDL and cholesterol esters are released into the hepatic cells and leter 
excreted through bile. This HDL mediated cholesterol transport from the 
peripheral tissues to the liver is called “Reverse Cholesterol Transport”. (39)  
The sole route of excretion of cholesterol is through bile in the form of 
cholesterol esters or as bile salts and this excretion needs prior esterification 
with PUFA. Thus PUFA is antiatherogenic. 
Some amount of cholesterol within the lipid core of HDL is exchanged for 
triglycerides present in VLDL and Chylomicons with the help of Cholesteryl 
Ester Transfer Protein (CETP). 
 
Fig 2: Figure Depicting Lipid Absorption, Endogenous And Exogenous Lipid 
Transport And Reverse Cholesterol Transport 
ADULT TREATMENT PLAN III GUIDELINES
(41) 
ATP III CLASSIFICATION OF TOTAL CHOLESTEROL 
Total Cholesterol  ATP III LEVELS IN mg/dL 
Desirable < 200 
Borderline High 200-239 
High  ≥ 240 
 
ATP III CLASSIFICATION OF LDL CHOLESTEROL 
LDL Cholesterol  ATP III LEVELS IN mg/dl 
Optimal < 100 
Near optimal/above optimal 100-129 
Borderline High 130-159 
High  160-189 
Very High ≥190 
 
 
 
ATP III CLASSIFICATION OF TRIGLYCERIDES 
TRIGLYCRIDES ATP III LEVELS IN mg/dl 
Normal  <150 
Borderline High 150-199 
High 200-499 
Very high  ≥ 500 
 
ATP III CLASSIFICATION OF HDL CHOLESTEROL 
HDL cholesterol  ATP III LEVELS IN mg/dl 
Low  < 40 
 High ≥60 
 
Serum total cholesterol is a fair indicator of LDL cholesterol levels. The 
Multiple Risk Factor Intervention Trial (MRFIT), The Framingham Heart Study  
and the Lipid Reasearch Clinics (LRC) have demonstrated a direct correlation 
between LDL cholesterol levels and the rate of new onset Coronary heart 
disease in previously healthy men and women. LDL cholesterol level more than 
100 mg/dl was found to be atherogenic. When triglyceride level exceeds 
200mg/dl, the amount of atherogenic remnant lipoproteins increases and 
heightens CHD risk. 
Non-HDL cholesterol comprises of the sum of VLDL and LDL cholesterol. 
These includes all Apo B containing lipoproteins. Serum total ApoB has a 
strong  predictive power for occurance of future cardiovascular disease.  So the 
non- HDL cholesterol can be used as an acceptable indirect marker for the total 
apolipoprotein B levels. 
When triglycerides level is less than 200 mg/dl, as VLDL does not increase 
sufficiently and so the non-HDL cholesterol levels correlates only with LDL 
cholesterol. Therefore the sum of VLDL and LDL cholesterol is of not much 
value in predicting CHD. In hypertriglyceridemic patients of levels more than 
200mg/dl, the VLDL is substantially raised. So LDL cholesterol level alone 
inadequately defines the risk for atherogenicity. In this scenario, non- HDL 
cholesterol will better characterize the concentrations of the atherogenic 
lipoproteins in patients with high triglyceride levels. When triglyceride level 
falls within the very high category of more than 500 mg/dl, a portion of the 
cholesterol resides within the non atherogenic larger VLDL as well as 
chylomicrons. So the non-HDL cholesterol may again prove to be less reliable 
in predicting the risk for future CHD. 
DYSLIPIDEMIA IN DIABETES MELLITUS 
The hyperlipdemia  in diabetes mellitus is a secondary hyperlipidemia. Insulin 
deficiency plays a major role in individuals with type 1 diabetes mellitus. 
Insulin deficiency causes impaired lipoprotein lipase activity and enhanced rates 
of lipolysis at the same time which ultimately leads increased levels of 
triglycerides and apo-B containing lipoproteins. Insulin resistance is the key 
factor in the pathogenesis of type 2 diabetes mellitus and relative insulin 
deficiency has a complementary role only.  
 
 
The major components of diabetic dyslipidemia are: 
A. High triglycerides 
B. Increased small dense LDL 
C. Decreased HDL(HDL Levels  inversely proportional to the triglyceride 
levels) 
D. Post prandial lipemia 
A.HYPERTRIGLYCERIDEMIA 
The most frequently dyslipidemic pattern in type 2 diabetes mellitus is elevated 
triglyceride levels and low HDL levels. The hypertriglyceridemia even precedes 
elevation in serum Cholesterol. 
TRIGLYCERIDE RICH LIPOPROTEINS (TRL) 
 The VLDL and Chylomicrons  and their remnants which contain a larger 
fraction of triglycerides in their lipid core are called Triglyceride Rich 
Lipoproteins or TRLs. High circulating levels of TRLs  form the key 
pathogenic factor in diabetic dyslipidemia. 
Metabolism of TRLs 
In normal individuals, the major steps in TRL metabolism are 
1. VLDL assembly and secretion 
2. Transport of TRLs to adipose tissue and Skeletal muscles and other 
peripheral tissues 
3. Hydrolysis of core triglycerides mediated by LpL. 
4. TRL remnant uptake by liver 
5. The lipoprotein cascade pathway ( progressive delipidation of       
VLDL) causing the flux of Apo B100. 
ABNORMAL VLDL METABOLISM IN DIABETES  
The important defects of dysmetabolism in diabetes are 
a.Increased VLDL and endogenous triglyceride production. 
     b. Delayed clearance of VLDL 
    c. Defects in the apoliproteins especially lipoprotein C. 
a. Increased VLDL and endogenous triglyceride production 
There is impaired Lipoprotein lipase (LpL) activity in the skeletal muscle 
and adipose tissue. There are also increased rates of lipolysis in these tissues 
causing elevated levels of free fatty acids in the plasma and increased flux of 
free fatty acids from peripheries to the liver. 
(42,43)
 Apolipoprotein B 
production by the liver is also enhanced in the insulin resistant states.
(44)
 All 
these factors contribute to increased triglyceride and VLDL synthesis by the 
liver.
(42) 
b. Delayed clearance of VLDL 
This is also secondary to decreased LpL activity in the peripheral tissues. 
The hepatic uptake of VLDL is also diminished. 
(43) 
c. Defect In Apolipoproteins There is increased apo B production in the 
liver. Apo C-III is the major apolipoprotein in VLDL and it plays a vital role 
in the metabolism of VLDL. 
(45,46)
 LpL activity is directly inhibited by apo C 
III 
(47)
and consequently TRLs with high levels of Apo CIII undergo a slower 
catabolism.
(48,49)
 Apo C III also hampers Apo E mediated receptor binding 
and impairs hepatic uptake of remnant particles.
(50,51)
 
In normal individuals, the larger buoyant, triglyceride rich subfraction of 
VLDL is produced only in the fasting state. There is a chylomicron flux from 
the intestine during the postprandial state. In diabetic states characterized by 
insulin resistance,this balance is altered and there is increased production of 
larger triglyceride rich VLDL from the liver even in the post prandial state. 
In short excessive VLDL production and decreased TRL clearance occurs in 
type 2 diabetes. 
B.INCREASED LEVELS OF SMALL DENSE LDL  
The hypertriglyceridemia in type 2 diabetes mellitus is more pronounced in 
the postprandial state. As described above, both the levels and the residence 
time of TRLs are prolonged. This promotes the accelerated exchange of core 
lipids between TRL and HDL and LDL particles with the help of Cholesterol 
Ester Transfer Protein (CETP). 
This exchange process loads HDL and LDL with triglyceride. The 
triglyceride rich LDL and HDL are more preferentially hydrolysed by the 
hepatic lipase resulting in the formation of smaller denser LDL and HDL. 
The hepatic lipase activity is augmented in diabetics.
(53,54)
 Thus the levels of 
small dense LDL is increased in Type 2 diabetes mellitus  irrespective of the 
LDL levels. 
C.DECREASED LEVELS OF HDL 
The triglyceride rich HDL particles are formed due the CETP mediated 
exchange of core lipids as described above. These small HDL particles 
are  more readily catabolised by hepatic lipase. In fact, there exists an 
inverse correlation between hypertriglyceridemia and HDL levels. 
 
D.POSTPRANDIAL LIPEMIA 
Mechanisms: 
1. In postprandial state, there is a flux of chylomicrons into the 
circulation. Triglycerides within larger lipoproteins like chylomicrons are 
catabolised at a faster rate than those within the VLDL. So there is 
impaired VLDL clearance during post prandial period. This 
dysmetabolism coupled with unbridled VLDL production by the liver 
lead to post prandial lipemia. 
2. Impaired Lipoprotein lipase activity 
(43) 
3. Impaired hepatic clearance of VLDL remnants. 
DIABETIC DYSLIPIDEMIA - A PRO-ATHEROGENIC STATE 
Hypertriglyceridemia leads to increased VLDL that acts a precursor to the 
production of small dense LDL and decreased HDL levels. The postprandial 
states leads to worsening of this dyslipemia. The critical level of triglycerides 
above which the small dense LDL is formed is found to be 13-15 mmol/dl. 
ATHEROGENCITY OF SMALL DENSE LDL 
Small dense LDL can diffuse easily into subendothelial space and hence is more 
atherogenic.
(56)
 They have high oxidizability due to low cholesterol content and 
high PUFA and apo B content. Depletion of vitamin E also increases its 
susceptibility to oxidation. These are also more slowly cleared by the receptors 
compared to large, buoyant LDL and have a prolonged circulation time. This is 
due to a conformational change in the Apo B by increase in triglyceride content 
or decrease in size. This allows more time for them to be oxidized and taken up 
by macrophages in extravascular spaces. 
The sd LDL has higher affinity for binding to arterial proteoglycans as well as 
higher permeability across endothelial barrier, resulting in faster production of 
Foam cells. The small dense LDL subfraction is also more readily  glycated 
according to Soran etal in their review article. This glycation further decrements 
receptor uptake. The glycated small dense LDL enhances its property of 
aggregation and binding affinity to arterial proteoglycans thus potentiationg its 
atherogenecity.  
Increased levels of sdLDL are also associated with elevated fibrinogen levels. 
(>2.90g/L)  independent of other risk factors. The association of 
hypertroglyceridemia and hyperfibrinogenemia may be a vital metabolic link to 
the atherogenic process. 
High sdLDL level is found to be associated with elevated concentrations of 
Plasminogen activator inhibitor protein-1 (PAI-1). The PAI-1 inhibits 
fibrinolysis  and increases incidence of macrovascular complication of diabetes 
mellitus. The sdLDL stimulates PAI-1 release from endothelial cells. The 
endothelial dysfunction induced by sdLDL   also contribute to atherogenicity .  
 Postprandial dyslipidemia is essentially a proinflammatory state. There is 
enhanced synthesis of tumor necrosis factor-alpha, C-reactive protein and 
interleukin-6. Many of the metabolic derangements occurring in postprandial 
dyslipidemia  have been linked to endothelial dysfunction, including a reduced 
clearance of remnant particles, increased free fatty acids levels, increased lipid 
oxidation, and increased vascular superoxide radical production. 
A metaanalysis including data from about 57 000 subjects from 17 studies 
demonstrated that triglyceride levels were an independent risk factor for 
cardiovascular disease.
(58)
 When adjusted for HDL cholesterol, 36 mmol/l 
elevation in plasma triglyceride levels was associated with a relative risk of 1.3 
in men and 1.8 in women. The Physician Health Study comprising of a study 
group of 14 ,916 men aged between 40–84 years, with a seven year follow up, 
indicated  that the non-fasting triglyceride concentrations strongly predicted risk 
of future myocardial infarction.
(58)
 Karpe and co-workers demonstrated that the 
five years progression rate of coronary lesions correlated with  the postprandial 
plasma concentration of small chylomicron remnants.
(59)
 Adjustment for the 
other risk factors like HDL, dense LDL and apolipoprotein B levels did not 
significantly alter the strength of the above association. The coronary 
angiography data furnished by Mero et al also suggest that small chylomicron 
remnants are mainly implicated in the progression of macrovascular 
complications. 
(60) 
Endothelial dysfunction, calculated by ultrasound as FMD, has also been 
correlated with high triglyceride excursions. Correlations between postprandial 
TRL, abnormal FMD and oxidative stress markers have been demonstrated, 
thus highlighting free radical production as a possible underlying mechanism. 
(61, 62) 
In vitro studies have demonstrated increased expression of adhesion molecules 
in endothelial cells after incubating with VLDL and chylomicrons. Lundman et 
al showed defect in endothelium-dependent relaxation after exposure to the 
triglyceride-containing fat emulsion Intralipid. 
(63, 64)
 An elegant study done by 
Silveira et al showed in vivo activation of factor XI by triglycerides 
(65)
. Other 
prothrombotic changes occurring with an oral fat meal are increased plasmin 
activator inhibitor-1 (PAI-1) activity and PAI-1 antigen. Significant correlations 
were also found between postprandial triglyceride levels and tumor necrosis 
factor-alpha and interleukin 6 levels as well as P-selectin levels. 
(66-68) 
 
 
HYPERGLYCEMIA 
(1) 
DIAGNOSTIC CRITERIA FOR DIABETES MELLITUS 
(1) 
1. A FPG of 7.0 mmol/L (126 mg/dL),or 
2. A glucose >11.1 mmol/L (200 mg/dL) 2 h after an oral glucose challenge 
 or  
3.An A1C of 6.5% warrant the diagnosis of DM .  
4.A random plasma glucose concentration of 11.1 mmol/L (200 mg/dL) 
accompanied by classic symptoms of DM (polyuria, polydipsia, weight loss) 
also is sufficient for the diagnosis of DM. 
Abnormal glucose homeostasis is defined as: 
 (1) FPG = 5.6–6.9 mmol/L (100–125 mg/dL), which is defined as IFG 
 (2) Plasma glucose levels between 7.8 and 11 mmol/L (140 and 199 mg/dL) 
following an oral glucose challenge, which is termed impaired glucose tolerance 
(IGT) 
 (3) A1C of 5.7–6.4%. 
 An A1C of 5.7–6.4%, IFG, and IGT do not identify the same individuals, but 
individuals in all three groups are at greater risk of progressing to type 2 
diabetes and have an increased risk of cardiovascular disease. Some use the 
term "prediabetes," "increased risk of diabetes" (ADA), or "intermediate 
hyperglycemia" (WHO) for this category.  
The current criteria for the diagnosis of DM emphasize that the A1C or the FPG 
as the most reliable tests for identifying DM in asymptomatic individuals. 
Treatment goals of type 2 diabetes mellitus
(1) 
Therapeutic goals are:  
1. Eliminate hyperglycemic symptoms 
2. Decrease or eliminate the chronic microvascular and macrovascular 
complications 
3. Achievement of a normal lifestyle as much as possible 
The symptoms usually subside when plasma glucose is less than 200 mg/dl 
but the second and third goals are difficult to attain.  
 
Treatment goals of adults with diabetes mellitus 
Index Goal 
Glycemic control 
A1C <7.0% 
Preprandial capillary plasma glucose 3.9–7.2 mmol/L (70–130 mg/dL) 
Peak postprandial capillary plasma glucose <10.0 <1.7 mmol/L (<180 mg/dL) 
Blood pressure <130/80 
Lipids 
Low-density lipoprotein <2.6 mmol/L (100 mg/dL) 
High-density lipoprotein >1 mmol/L (40 mg/dL) in men >1.3 mmol/L 
(50 mg/dL) in women  
Triglycerides <1.7 mmol/L (150 mg/dL) 
 
POSTPRANDIAL HYPERGLYCEMIA
(1) 
In normal individuals the postprandial glucose load causes rise in insulin and 
fall in glucagon. Insulin is an anabolic hormone and it promotes the storage 
of carbohydrate. Majority of the postprandial glucose is utilized by skeletal 
muscles that are facilitated by insulin stimulated glucose uptake. 
 In insulin resistance states there is impaired glucose utilization by insulin 
sensitive tissues as well as increased hepatic glucose output. Both these 
factors contribute to hyperglycemia. The fasting plasma glucose levels are 
mainly determined by the increased hepatic glucose output where as 
postprandial hyperglycemia is caused by decreased peripheral glucose usage. 
In skeletal muscles glycogen formation is impaired to a greater degree than 
the oxidative glucose metabolism through glycolysis 
 
HYPERGLYCEMIA AND COMPLICATIONS OF DIABETES 
MELLITUS 
The exact mechanism through which chronic hyperglycemia contributes to the 
macrovascular complications of diabetes mellitus is unknown. Four prominent 
theories have been proposed to elucidate how hyperglycemia leads to diverse 
cellular and organ dysfunction in diabetes mellitus.
(1)
 These theories are not 
mutually exclusive.  
1. Increased Production of Advanced Glycosylation End Products (AGEs). 
2. Increased Metabolism through Polyol Pathway 
3.  Activation of Protein Kinase C (PKC ) 
4.  Increased Flux through the Hexosamine Pathway . 
A novel hypothesis is that hyperglycemia may lead to epigenetic changes in the 
affected cells. 
1. Increased Production Of Advanced Glycosylation End Products 
(AGEs). 
Advanced Glycosylation End Products (AGEs) are formed as a result of 
glycation reaction which is a non enzyme mediated addition of a 
carbohydrate to a protein. In diabetes mellitus, non enzymatic 
glycosylation results from the interaction of glucose with amino groups 
on intracellular and extracellular proteins. The intercellular 
hyperglycemia, especially in endothelial cells, result in increased levels 
of NADH and FADH  which disrupts the Electron Transport Chain. This 
ultimately causes mitochondrial production of Reactive Oxygen Species 
which damage DNA. These abnormal metabolites formed, activate 
multiple pathogenic mechanisms, one of which includes increased 
production of AGEs. The serum level of AGEs correlates with the degree 
of hyperglycemia.  
2.Increased Metabolism Through Polyol Pathway 
POLYOL PATHWAY 
The sorbitol (polyol) pathway (not found in liver) is responsible for fructose 
formation from glucose. Glucose is reduced to sorbitol by aldose reductase, 
followed by oxidation of sorbitol to fructose in the presence of NAD+ and 
sorbitol dehydrogenase (polyol dehydrogenase). 
          Intracellular glucose is predominantly metabolized by phosphorylation 
and subsequent glycolysis. In hyperglycemic states, some glucose is converted 
to sorbitol by the enzyme aldose reductase The polyol pathway increases in 
activity as the glucose concentration rises in diabetes especially in those tissues 
that are not insulin-sensitive, ie. lens, peripheral nerves, and renal glomeruli. 
Sorbitol does not diffuse through cell membranes easily and  
accumulates,causing osmotic damage. Increased sorbitol concentration alters 
redox potential, increases cellular osmolality, generates reactive oxygen species, 
and also  leads to other types of cellular dysfunction 
3.Activation Of Protein Kinase C (PKC ) 
Hyperglycemia enhances the formation of diacylglycerol leading to activation 
of protein kinase C (PKC).  PKC alters the gene transcription of fibronectin, 
contractile proteins, type IV collagen and extracellular matrix proteins in 
endothelial cells and neurons. Inhibitors of PKC are undergoing clinical trials as 
potential antiglycemic agents. 
4.Increased Flux Through The Hexosamine Pathway . 
Hyperglycemia increases the flux through the hexosamine pathway that forms 
fructose -6-phosphate which is a substrate for O-linked glycosylation and 
proteoglycan production. The hexosamine pathway may alter function by 
glycosylation of proteins like endothelial nitric oxide synthase(NOS) or by 
altering gene expression of transforming growth factor (TGF-beta) or 
plasminogen activator inhibitor-1 (PAI-1). 
Growth factors like platelet-derived growth factor(PDGF), epidermal growth 
factor(EGF), insulin-like growth factor I(IGF-I), growth hormone(GH), basic 
fibroblast growth factor(FGF), and even insulin, have been postulated  to play a 
role in both macrovascular and microvascular complications. 
 A possible unifying mechanism is that hyperglycemia leads to increased 
production of reactive oxygen species (ROS) within the mitochondria. These 
compounds may trigger and promote all four of the pathways mentioned above. 
This hyperglycaemia-induced oxidative stress ultimately results in modification 
of intracellular proteins resulting in an altered function, DNA damage, 
activation of the transcription factor nuclear factor-kB, causing abnormal 
changes in gene expression, decreased production of nitric oxide, and increased 
expression of cytokines, growth factors and procoagulant and proinflammatory 
molecules. 
Although hyperglycemia serves as the initial common factor for complications 
of diabetes mellitus, it is still unknown whether the same pathophysiologic 
processes are operative in all complications or whether some pathways 
predominate in certain organs. 
HYPERGLYCEMIA AND ATHEROSCLEROSIS 
Hyperglycemia acts synergistically with other cardiovascular risk factors. Even 
after controlling all other potential cardiovascular risk factors, type 2 DM 
increases the risk of cardiovascular death about twofold in men and fourfold in 
women. Insulin resistance, evidenced by increased serum insulin levels, is 
associated with an enhanced  risk of cardiovascular complications in individuals 
with Diabetes Mellitus. Individuals with insulin resistance and uncontrolled 
type 2 DM with have high levels of plasminogen activator inhibitors (PAI-1) 
and fibrinogen, all of which augments  the coagulation process and hampers 
fibrinolysis, thus promoting thrombotic events. Diabetes is also associated with 
endothelial, platelet and vascular smooth-muscle dysfunction. 
(1) 
The glycemic goal for individuals with acute cardiovascular event and long-
standing diabetes remains uncertain. In both the DCCT (type 1 diabetes) and the 
UKPDS (type 2 diabetes), major cardiovascular events were not decreased by 
stringent treatment during the trial but were reduced at follow-up done 10–17 
years later. This effect has been called legacy effect or metabolic memory. 
Current recommendations do not suggest more stringent glucose lowering in 
this patient population.  
Several epidemiological studies across the globe have shown an association 
between 2 hour post prandial glucose levels and the occurrence of 
cardiovascular disease. A meta-analysis of 20 studies with more than 95 000 
people demonstrated a continuous relationship between post load glucose levels 
and cardiovascular disease risk even extending into the non-diabetic range.
(70)
 
The Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in 
Europe (DECODE) study demonstrated that the postprandial glucose 
concentrations, even in subjects with normal fasting glucose, were associated 
with cardiovascular mortality, independent of fasting plasma glucose levels.
(71) 
Chronic hyperglycemia has been associated with endothelial dysfunction as 
measured by FMD. 
(72)
 Also, circulating ICAM-1 plasma levels significantly 
increased in both diabetic and normal subjects after an oral glucose tolerance 
test, demonstrating endothelial cell activation. 
(73) 
Ceriello and co-workers have demonstrated that postprandial hyperglycemia is 
accompanied by alteration and dysregulation of the coagulation system. 
(74, 75) 
An oral glucose load was found to cause a shortening of the half life of 
fibrinogen and an elevation of  plasma fibrinopeptide A and the prothrombin 
and factor VII fragments. In addition, acute hyperglycaemia resulted in a 
transient hyper-reactivity of platelets to high shear stress.
(76)
 This was combined 
with a significant elevation of plasma vWF in diabetic patients. These findings 
suggest that postprandial hyperglycemia may induce a hypercoagulable state. 
Consecutive pulses of intravenous glucose increased circulating concentrations 
of inflammatory cytokines like interleukin-6 and tumor necrosis factor-alpha to 
a greater extent than similar blood glucose levels when kept stable during a 
hyperglycemic clamp. This effect was more pronounced in 
subjects with impaired glucose tolerance.
(77,78)
 The demonstration by Risso et al 
that intermittent high glucose levels induced more apoptosis than constant 
corresponding glucose levels in human umbilical vein endothelial cells also 
supports the role of postprandial glucose in cytotoxic damage. Thus excursions 
in blood glucose levels as it occurs in the postprandial states, may induce a pro 
inflammatory response and cytotoxic effect. 
(79-81) 
Diabetic individuals have an increased incidence of congestive heart failure. 
The etiology of increased risk is probably multi factorial. This includes factors 
such as myocardial ischemia from atherosclerosis, hypertension, and myocardial 
cell dysfunction secondary to chronic hyperglycemia. Cerebrovascular disease 
is also increased by three fold in diabetic population.
(1) 
HbA1c 
Blood glycated hemoglobin (also called hemoglobin A1C, glycohemoglobin, 
and glycosylated hemoglobin [HbA1c]) changes in a dynamic way and reflects 
the mean blood glucose concentration over the previous six to eight weeks. 
(82) 
It is formed by non enzymatic addition of sugar residue to amino groups of 
Haemoglobin. Glucose can attach to many proteins via a nonenzymatic, 
posttranslational process named Glycation reaction. 
It is formed by two steps 
(1)A reversible reaction leads to the formation of an aldimine  
(2) Followed by an Amadori rearrangement to form an irreversible 
ketoamine. 
The measurement of glycated haemoglobin is free of day to day glucose  
fluctuations. It is unaffected by exercise or recent food ingestion. 
The recent glucose values contribute more to HbA1c. . The glucose in preceding 
1 month contributes 50% of the total value. The HbA1c levels increase 1 week 
after stopping therapy. The value does not fall for 2-4 weeks after starting 
therapy. The half time is about 35 Days. 
 
CLINICAL UTILITY
(82) 
The represents integrated value of blood glucose over 6-8 wks. 
HbA1c is the corner stone of DCCT and UKPDS studies. If mean annual 
HbA1c is less than 1.1 times upper limit of normal renal &retinal complications 
are rare. If HbA1c is more than 1.7 complications occur in 70% of the patients. 
ADA (2011) included HbA1c value as a diagnostic criteria for diabetes 
mellitus: 
 Less than 5.6 = normal 
 5.7 to 6.4 = prediabetic  
 6.5 and above = diabetic  
The ACCE treatment guidelines for starting therapy in diabetics are also based 
on HbA1c values. 
 
HbA1c AND MACROVASCULAR COMPLICATIONS OF DIABETES 
MELLITUS 
(83, 84) 
There is well documented relationship between HbA1c and microvascular 
complications of Diabetes mellitus. One percentage increase in HbA1c was 
associated with 37% increase in microvascular complications. 
The relationship between HbA1c and macrovascular complications of diabetes 
mellitus is complex. For one percentage reduction in HbA1c, the cardiovascular 
risk reduction is in the range of  40% as per DCCT study  and upto 14% as per 
UKPDS study. However, as per ACCORD trial, no statistically significant 
improvement was found in macrovascular complication with improvement in 
HbA1c level. Mean progression of intima-media thickness of carotid artery was 
significantly less in intensive therapy compared with conventional therapy 
(0.032 versus 0.046 mm).  
As per a study conducted by Hung et al, HbA1c was significantly associated 
with CIMT independent of conventional cardiovascular risk factors, FPG, and 
post challenge glucose. The results implied that HbA1c could be more 
informative of cardiovascular risk as compared with FPG and post challenge 
glucose. Studies done by Hung CS demonstrated that Haemoglobin A1c is 
significantly associated with carotid intima-media thickness in a Chinese 
population based study. 
(83) 
 
 
 
 
 
 
CAROTID INTIMA MEDIA THICKNESS 
 Intima-media thickness (IMT) is a measurement of the thickness of the tunica 
intima and the tunica media which are the innermost two layers of the arterial 
wall. The IMT measurement is usually done by external ultrasound but can also 
be done by internal, invasive ultrasound catheters (IVUS). 
IMT is used to detect the presence of atherosclerotic changes and, more 
contentiously, to track the progression, regression or arrest of atherosclerosis. 
Ultrasound IMT measurements have been first proposed and in vitro validated 
in Milan by Paolo Pignoli in 1984. 
(86)
 The use of IMT as a non-invasive method  
to track atherosclerotic changes in arterial walls has increased substantially 
since the mid-1990s. 
 Since the 1990s, several small clinical and larger scale pharmaceutical trials 
have used Carotid artery IMT as a surrogate endpoint for evaluating the 
progression or regression of atherosclerotic cardiovascular disease. Many 
studies have documented the relation between the carotid IMT and the presence 
and severity of atherosclerosis. In 2003, the European Society of Hypertension–
European Society of Cardiology guidelines for the management of arterial 
hypertension advocated and recommended the use of IMT measurements in 
high-risk patients to help identify target organ damage. In 2010, the American 
Heart Association and the American College of Cardiology recommended the 
use of IMT on intermediate risk patients if routine risk classification was not 
satisfactory. 
Patients with early atherosclerotic changes are usually asymptomatic. They 
become symptomatic only when the percentage of luminal obstruction becomes 
significant. Carotid IMT measurement using Doppler ultrasound has been 
shown as a non invasive and quantitative tool to detect and assess these early 
changes. 
The histopathological profile of atherosclerosis changes also correlates well 
with the carotid IMT measurements. The initial atherosclerotic changes on the 
vessel are noticeable only in the vessel wall. As the atherosclerotic changes 
progress, there is compensatory dialatation of the affected artery so as to 
maintain the size of the arterial lumen. 
(86)
 So there is only a minimal reduction 
in the lumen size. The decline in lumen size is visible only when the stenosis 
has progressed to at least 40 %. This may be the reason for the inadequacy of 
angiography as a tool to look for early atherosclerotic changes since it measures 
only luminal encroachment. 
The B mode ultrasound is advantageous over angiogram because of its cost 
effectiveness as well as its efficacy and precision in diagnosing early 
atherosclerotic changes. 
(88)
Serial measurements can also be made with relative 
ease to assess the course of intimal changes. This test can also be used in 
patients irrespective of the clinical status as it is non invasive and quantitative 
method. The lack of radiation exposure is another added benefit over 
angiography. As the carotid artery is an elastic artery, the muscular media is 
relatively small. Hence, thickening of the carotid arterial wall is due essentially 
to intimal thickening. 
When using B mode ultrasonography, the CIMT is defined as the linear distance 
between the two ultrasonic interphases seen. These two interphases make the 
boundaries between adventitia and media and lumen and intima. An increase in 
CIMT reflects not only the local pathology but also corresponds to generalised 
atherosclerosis.  
Patient should be placed in supine position with neck slightly extended. 
Bilaterally the arterial scans are performed in the anteroposterior projections. 
The scanning of extracranial common carotid arteries or internal carotid artery 
is performed according to evading edge of of the second echogenic line. The 
first line represents lumen intimal interphase and the second line represents the 
tunica adventitia. The linear distance between these two interphases gives us the 
CIMT. Three determinations of the IMT are done at the site of maximum 
thickness of the artery, one centimeter downstream and one centimeter upstream 
from the first point. The mean of the three measurements is calculated. The 
normal IMT range of the carotid artery as evaluated by B mode ultrasonography 
is about 0.74 ± 0.14mm. 
(89) 
  
DYSLIPIDEMIA  AND HYPERGLYCEMIA: CO PLAYERS IN THE 
POSTPRANDIAL DYSMETABOLISM 
Insulin resistant states and type 2 diabetes are characterized by high circulating 
levels of atherogenic lipid particles due to an increased supply of fatty acids to 
the liver and defective hepatic clearance of lipoproteins. The postprandial state 
further exaggerates the lipid abnormalities, with an added on adverse effect of 
meal induced hyperglycaemia. These postprandial dysmetabolic events 
independently and cumulatively increase the production of Reactive Oxygen 
Species resulting in oxidative stress and functional abnormalities of the vascular 
endothelium at multiple  levels, including impairment of vasoreactivity, 
increased vascular permeability, increased coagulation and inflammation 
activation.Collectively, postprandial dysmetabolism and the associated 
Fig 3: MEASUREMENT OF 
CIMT: three measurements are 
taken- one at the Common carotid 
artery bifurcation and one each one 
centimeter proximal and distal to 
the bifurcation 
 
oxidative stress may link insulin resistance and type 2 diabetes to the 
disproportional incidence of macrovascular complications in these high risk 
populations. 
 
Fig 4: The Pathogenesis of Postprandial Dysmetabolism 
 
To summarise, the high morbidity and mortality associated with macrovascular 
complications of type 2 diabetes is to some extent due to a prolonged and 
exaggerated postprandial dysmetabolic state. So while assessing the true 
atherogenic risk and exposure of the vascular system especially in high risk 
patients, one should abandon the solely glucose centred view and use 
physiological tests and therapeutic regimes capable of combating the glucose 
and lipid load. 
 
MATERIAL AND METHODS 
This study was done at Government Royapettah Hospital, Chennai between 
January 2013 to September 2013 . 
STUDY DESIGN AND PATIENT SELECTION: 
This is a cross sectional, comparative  study in which 100 patients with type 2 
diabetes mellitus in the age group of 35-65 years, with average duration of 
diabetes between one to six years are included. The study design was approved 
by the Ethical Committee of the institution. 
Inclusion criteria : 
All patients with type 2 diabetes mellitus with normal ECG and normal 
echocardiogram  
Exclusion criteria : 
1. Prior history of Ischemic heart disease as determined by history and 
ECG 
2. Patients on lipid lowering drugs, thiazides, betablockers 
3. Patients with history of CVA/TIA 
4. Patients with clinical or imaging evidence of Peripheral vascular 
disease or history of limb amputation 
5. Patients with history of bariatric surgery 
6. Known cases of hypothyroidism 
7. Patients with chronic complications of diabetes like nephropathy, 
retinopathy. 
8. Patients with history or clinical findings suggestive of familial 
hyperlipidemias.  
9. Patients with known hepatic disease. 
Patients on oral hypoglycemic agents, antihypertensive drugs (ACE inhibitors 
or AT II antagonists) were not excluded from the study, 
The following investigations were done in all the patients prior to entering into 
the study: 
 Haemoglobin  
 Total Leukocyte Count, Differential Leukocyte Count 
 ESR 
 Random Blood Sugar 
 Blood Urea 
 Serum Creatinine 
 Liver function tests 
 Urine Microscopy for sugar and albumin 
 ECG or 2D Transthoracic Echocardiogram 
 STANDARDIZED MEAL TEST 
A standardized mixed meal was given to all the patients after an overnight fast. 
The meal consisted of three idlis and a standard serving of sambar and a 
standard serving of coconut chutney. The total energy content of the standard 
meal was 9 Kcal/kg, with 60% of the total energy from carbohydrates, 20% of 
the energy from fat and 20 % of the energy from proteins. Blood samples were 
drawn before and 4 hours after the standardized test meal. The HbA1c, fasting 
and postprandial lipid profile levels and glucose levels were estimated. Fasting 
and postprandial triglycerides, total Cholesterol, HDL, VLDL were measured 
by standard laboratory technique. The Friedwald’s formula was used to 
calculate LDL cholesterol  
Friedwalds Formula : 
LDL cholesterol =  Total Cholesterol – (HDL+Triglycerides/5) 
MEASUREMENT OF CAROTID INTIMA MEDIA THICKNESS: 
The CIMT was measured by Doppler Ultrasonogram. Carotid Artery Doppler 
was done by B-mode ultrasound by using a 7.5 MHZ transducer.   
 
 
 STATISTICAL ANALYSIS 
Data was entered in Windows Excel format. Frequency tables and measures of 
central tendency (mean) and measures of dispersion (Standard Deviation) and 
all statistical analyses were calculated by using the statistical package SPSS- 20.   
 
 
 
 
 
 
 
 
OBSERVATION AND RESULTS 
1. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO AGE AND 
CORRELATION WITH CIMT 
Age Categories No. Mean CIMT Std. Deviation p value 
35-45 37 1.513 0.6176 
0.674 46-55 41 1.449 0.5642 
Above 55 22 1.593 0.6966 
 
TABLE 1: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO AGE AND CORRELATION WITH 
CIMT 
The Mean Age of the total study group was 48± 7.2 years 
Among the total 100 patients, 
 37 of them were in the age group of 35 to 45 and the mean CIMT in this age 
group was 1.513 ±0.6176 
41 of them were in the age group of 46 to 45 and the mean CIMT in this age 
group was 1.449±0.5642 
22 of them were in the age group of above 55 years and the mean CIMT in this 
age group was 1.593±0.6966 
There was no statistically significant correlation between the age and the CIMT 
values (p value=0.674) 
 Figure 1: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO AGE 
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2. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SEX AND 
CORRELATION WITH CIMT 
Sex No. Mean CIMT Std. Deviation P value 
Male 62 1.593 0.6255 
0.064 
Female 38 1.360 0.5651 
 
TABLE 2: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SEX AND CORRELATION WITH 
CIMT 
In the study group, 62 persons were male and they had a mean CIMT value of 
1.593 ±0.6255 
In the study group, 38 persons were female and they had a mean CIMT value 
of 1.360±0.5651 
There was no statistical correlation between the sex and CIMT values (p value = 
0.064)  
There was also no statistical correlation between the duration since diagnosis of 
type 2 diabetes mellitus and CIMT values (p value = 0.368). The mean duration 
from the diagnosis of type 2 DM in the study group was 2.7± 1.18 years 
 Figure 2: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SEX 
 
 
Figure 3: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SEX AND CORRELATION WITH 
CIMT 
 
 
 
 
62 
38 
Male 
Female 
1.2 
1.25 
1.3 
1.35 
1.4 
1.45 
1.5 
1.55 
1.6 
Male Female 
1.593 
1.36 
Mean CIMT 
3. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO MODE OF 
TREATMENT AND CORRELATION WITH CIMT 
Treatment category No. Mean CIMT Std. Deviation p value 
OHA 80 1.498 0.6183 
0.832 
Insulin 20 1.531 0.5956 
 
TABLE 3: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO MODE OF TREATMENT AND 
CORRELATION WITH CIMT 
In the study population, 80 people were prescribed oral hypoglycemic agents 
and the mean CIMT value was 1.498±0.6183. 
In the study population, 20 people were prescribed oral hypoglycemic agents 
and the mean CIMT value was 1.531±0.5956. 
The mode of treatment did not significantly influence the CIMT values (p value 
= 0.832). 
  
Figure 4: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO MODE OF TREATMENT 
 
 
Figure 5: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO MODE OF TREATMENT AND CORRELATION WITH 
CIMT 
 
80 
20 
OHA 
Insulin 
1.48 
1.49 
1.5 
1.51 
1.52 
1.53 
1.54 
OHA 
Insulin 
1.498 
1.531 
Mean CIMT 
4. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SMOKING AND 
CORRELATION WITH CIMT 
Smoking No. Mean CIMT Std. Deviation p value 
Yes 24 1.681 0.6852 
0.104 
No 76 1.449 0.5793 
 
TABLE 4: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SMOKING AND CORRELATION 
WITH CIMT. 
In the study population, 24 were smokers and the mean CIMT was 
1.681±0.6852.  
In the study population, 76 were non smokers and the mean CIMT was 
1.449±0.5793. 
Even thought the mean CIMT values were higher among the smokers, there was 
no statistically significant correlation between smoking and CIMT values. (p 
value = 0.104) 
 
 Figure 6: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SMOKING 
 
Figure 7: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SMOKING AND CORRELATION 
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5. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO ALCOHOL 
INTAKE AND CORRELATION WITH CIMT 
Alcohol No Mean Std. Deviation p value 
Yes 37 1.547 0.6487 
0.595 
No 63 1.479 0.5916 
 
TABLE 5: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO ALCOHOL INTAKE AND 
CORRELATION WITH CIMT 
In the study population, 37 persons gave history of alcohol consumption and 
the mean CIMT values were 1.547±0.6487 
In the study population, 63 persons gave no history of alcohol consumption 
and the mean CIMT values were 1.479±0.5916. 
Though the mean CIMT values were higher in the alcohol consuming group, the 
difference was not statistically significant. (p value= 0.595) 
 
 
 Figure 8: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO ALCOHOL INTAKE 
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6. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SMOKING AND 
ALCOHOL INTAKE 
Smoke and alcohol No. Mean CIMT Std. Deviation p value 
Yes 15 1.539 0.7255 
0.815 
No 85 1.498 0.5933 
 
TABLE 6: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SMOKING AND ALCOHOL 
INTAKE. 
In the study population 15 people gave history of smoking as well as alcohol 
consumption and in the group the mean CIMT value was 1.539 ±0.7255. 
  
Figure 10: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SMOKING AND ALCOHOL INTAKE
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7. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SYSTEMIC 
HYPERTENSION AND CORRELATION WITH CIMT 
Hypertension No. Mean CIMT Std. Deviation p value 
Yes 32 1.604 0.5978 
0.264 
No 68 1.551 0.6158 
 
TABLE 7: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SYSTEMIC HYPERTENSION AND 
CORRELATION WITH CIMT 
In the study population, 32 people gave history of systemic hypertension and 
the mean CIMT was 1.604±0.5978. 
In the study population, 68 people were not hypertensives and the mean CIMT 
was 1.551±0.6158. 
Although the mean CIMT was higher in hypertensive group, the difference was 
not statistically significant. (p value = 0.264)  
In the study population, the mean Systolic Blood Pressure was 126.34 ±13.85 
mm of Hg and Diastolic Blood Pressure was 78.28± 11.05 mm of Hg. 
Both the Systolic Blood Pressure (p value=0.151) and And Diastolic Blood 
Pressure (p value=0.219) readings did not correlate with CIMT values in a 
statistically significant manner. 
CORRELATION OF BMI VALUES WITH CIMT 
The BMI values did not correlate with CIMT values in a statistically significant 
manner. (p value=0.082) 
  
Figure 12:DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO SYSTEMIC HYPERTENSION 
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8. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
FASTING CHOLESTEROL AND CORRELATION WITH CIMT 
FTC (mg %) No. Mean CIMT (mm) Std. Deviation p value 
< 200 88 1.433 0.5928 
0.001 
≥ 200 12 2.030 0.4875 
 
TABLE 8: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO FASTING CHOLESTEROL AND 
CORRELATION WITH CIMT 
 
The Mean Fasting total Cholesterol of the total study group was 166± 38.2 mg% 
In the study population, 88 people had fasting cholesterol less than 200 mg% 
and the mean CIMT was 1.433±0.5928 mm. 
In the study population, 12 people had fasting hypercholesterolemia (cholesterol 
values above 200 mg %) and the mean CIMT was 2.030±0.4875mm 
 
The fasting cholesterol values showed a positive correlation with CIMT 
values which was statistically significant. (p value = 0.001) 
 Figure 14:DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO FASTING CHOLESTEROL 
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9. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
POSTPRANDIAL CHOLESTEROL VALUES AND CORRELATION 
WITH CIMT 
PPTC (mg %) No. Mean CIMT Std. Deviation p value 
< 200 26 1.062 0.4840 
<0.001 
≥200 74 1.660 0.5759 
 
The Mean post prandial Total Cholesterol of the total study group was 246± 
53.1 mg% 
In the study population, 26 people had postprandial cholesterol less than 200 
mg% and the mean CIMT was 1.062±0.4840mm. 
in the study population,74 people had postprandial hypercholesterolemia 
(cholesterol values above 200 mg%) and the mean CIMT was 1.660±0.5759mm 
The postprandial cholesterol values showed a positive correlation with 
CIMT values which was statistically significant.(p value < 0.001). 
The VLDL values did not show a statistically significant correlation with the 
CIMT values (p=0.346). The mean VLDL cholesterol in the study group was 
32.2 ±13.7 mg%. 
 Figure 16: . DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO POSTPRANDIAL CHOLESTEROL VALUES 
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10. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO  
FASTING HDL VALUES AND CORRELATION WITH CIMT 
FHDL (mg %) No. Mean CIMT(mm) Std. Deviation p value 
<= 40 91 1.516 0.6191 
0.551 
> 40 9 1.388 0.5393 
 
TABLE 10: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO FASTING HDL VALUES AND 
CORRELATION WITH CIMT 
 
The Mean fasting HDL of the total study group was 33.7 ±5.98mg% 
In the study population, 91 people had fasting HDL values less than 40mg% and 
the mean CIMT was 1.516±0.6191mm. 
In the study population, 9 people had fasting HDL values more than 40 mg% 
and the mean CIMT was 1.388±0.5393mm. 
The fasting HDL did not show a statistically significant correlation with CIMT 
value. (p value=0.551) 
 
 Figure 18:. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO  FASTING HDL VALUES 
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11. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
POSTPRANDIAL HDL VALUES AND CORRELATION WITH CIMT 
PPHDL (mg %) No. Mean CIMT(mm) Std. Deviation p values 
<= 40 84 1.522 0.6175 
0.517 
> 40 16 1.413 0.5857 
 
TABLE 11: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO POSTPRANDIAL HDL VALUES 
AND CORRELATION WITH CIMT 
 
The mean postprandial HDL of the total study group was 34.9± 6.72mg% 
In the study population, 84 people had postprandial HDL values less than 
40mg% and the mean CIMT was 1.522±0.6175mm. 
In the study population, 16 people had postprandial HDL values more than 40 
mg% and the mean CIMT was 1.413±0.5857mm. 
The postprandial HDL values did not show a statistically significant correlation 
with CIMT values. (p value=0.551) 
  
Figure 20:DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO POSTPRANDIAL HDL VALUES 
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12.  DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
FASTING LDL VALUES AND CORRELATION WITH CIMT 
FLDL (mg 
%) 
No. 
Mean CIMT 
(mm) 
Std. 
Deviation(mm) 
F value p value 
< 100 60 1.492 0.5833 
2.754 0.069 100-129 34 1.429 0.6457 
≥ 130 6 2.050 0.4774 
 
TABLE 12: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO FASTING LDL VALUES AND 
CORRELATION WITH CIMT 
 
The mean fasting LDL of the total study group was 93.9±26.9mg% 
In the study population, 60 people had fasting LDL values less than 100mg% 
and the mean CIMT was 1.492±0.5833mm. 
In the study population, 34 people had fasting LDL values between 100mg% 
and 129 mg % and the mean CIMT was 1.429±0.6457mm. 
In the study population, 6 people had fasting LDL values more than 130 mg% 
and the mean CIMT was 2.050±0.4774mm. 
 
 Even though the mean CIMT values increased in magnitude with rise in  LDL 
values, the fasting LDL did not show a statistically significant correlation with 
CIMT value. (p value=0.551) 
 Figure 22: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO FASTING LDL VALUES 
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13. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
POSTPRANDIAL LDL VALUES AND CORRELATION WITH CIMT 
PPHDL (mg %) No. Mean CIMT (mm) 
Std. 
Deviation 
F value p value 
< 100 24 1.337 0.5554 
1.666 0.194 100-129 25 1.462 0.6321 
>= 130 51 1.604 0.6172 
 
TABLE13. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO POSTPRANDIAL LDL VALUES 
AND CORRELATION WITH CIMT 
 
The mean post prandial LDL of the total study group was 128.5±35.08mg% 
In the study population, 24 people had postprandial LDL values less than 
100mg% and the mean CIMT was 1.337±0.5554mm. 
In the study population, 25 people had postprandial LDL values between 
100mg% and 129 mg% and the mean CIMT was 1.462±0.6321mm. 
In the study population, 51 people had postprandial LDL values more than 130 
mg% and the mean CIMT was 1.604±0.6172mm. 
 Even though the mean CIMT values increased in magnitude with rise in LDL 
values, the postprandial LDL did not show a statistically significant correlation 
with CIMT value. (p value=0.194) 
 Figure 24: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO POSTPRANDIAL LDL VALUES  
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14.  DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
FASTING TRIGLYCERIDE VALUES AND CORRELATION WITH 
CIMT 
FTG (mg%) No. Mean CIMT(mm) Std. Deviation F value p value 
< 150 63 1.235 0.5421 
24.956 <0.001 150-199 19 1.899 0.4285 
200-499 18 2.032 0.4110 
 
TABLE 14: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO FASTING TRIGLYCERIDES 
VALUES AND CORRELATION WITH CIMT 
 
The mean fasting triglycerides of the total study group was 156±60.2 mg% 
In the study population, 63 people had fasting triglycerides values less than 
150mg% and the mean CIMT was 1.235±0.5421mm. 
In the study population, 19 people had fasting triglycerides values between 
150mg% and 199 mg % and the mean CIMT was 1.899±0.4285mm. 
In the study population, 18 people had fasting triglycerides values more than 
200 mg% and the mean CIMT was 2.032±0.4110mm. 
The fasting triglycerides values showed a positive correlation with CIMT 
values which was statistically significant. (p value < 0.001) 
 Figure 26: .  DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO FASTING TRIGLYCERIDE VALUES 
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15. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
POSTPRANDIAL TRIGLYCERIDES VALUES AND CORRELATION 
WITH CIMT 
PPTG (mg %) No. Mean CIMT (mm) 
Std. 
Deviation 
F value p value 
< 200 43 0.961 0.3389 
58.311 <0.001 
200-299 36 1.797 0.3780 
300-399 15 2.041 0.4420 
≥ 400 6 2.298 0.3270 
 
TABLE15. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO POSTPRANDIAL 
TRIGLYCERIDES VALUES AND CORRELATION WITH CIMT 
The mean Post prandial Triglycerides of the total study group was 235± 9.9 
mg% 
In the study population, 43 people had postprandial triglycerides values less 
than 200mg% and the mean CIMT was 0.961±0.3389mm. 
In the study population, 36 people had postprandial triglycerides values between 
200mg% and 299 mg% and the mean CIMT was 1.797±0.3780mm. 
In the study population, 15 people had postprandial triglycerides values between 
300mg% and 399 mg% and the mean CIMT was 2.041±0.4420mm. 
In the study population, 6 people had postprandial triglycerides values more 
than 400 mg% and the mean CIMT was 2.298±0.3270mm. 
The post prandial triglycerides values showed a positive correlation with 
CIMT values which was statistically significant. (p value <0.001) 
 
 Figure 28: . DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO POSTPRANDIAL TRIGLYCERIDES VALUES 
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16.  DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
FASTING BLOOD SUGAR VALUES AND CORRELATION WITH 
CIMT 
FBS (mg %) No. 
Mean 
CIMT(mm) 
Std. 
Deviation 
F value p value 
< 100 28 1.014 0.4089 
22.304 <0.001 
100-149 56 1.548 0.5414 
150-199 12 2.120 0.3019 
200-249 4 2.478 0.2138 
 
TABLE 16: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO FASTING BLOOD SUGAR 
VALUES AND CORRELATION WITH CIMT 
The mean Fasting Blood Sugar of the total study group was 122± 35.1 mg% 
In the study population, 28people had fasting blood sugar values less than 
100mg% and the mean CIMT was 1.014±0.4089mm. 
In the study population, 56 people had fasting blood sugar values between 
100mg% and 149 mg% and the mean CIMT was 1.548±0.5414mm. 
In the study population, 12 people had fasting blood sugar values between 
150mg% and 199 mg% and the mean CIMT was 2.120±0.3019mm 
In the study population, 4 people had fasting blood sugar values between 200 
mg% and 249 mg% and the mean CIMT was 2.478±0.2138mm. 
The fasting blood sugar values showed a positive correlation with CIMT 
values which was statistically significant. (p value < 0.001) 
 Figure 30: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO FASTING BLOOD SUGAR VALUES 
 
 
Figure 31: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO FASTING BLOOD SUGAR VALUES AND 
CORRELATION WITH CIMT 
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 17.  DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
POSTPRANDIAL BLOOD SUGAR VALUES AND CORRELATION 
WITH CIMT 
PPBS (mg %) No. 
Mean 
CIMT(mm) 
Std. 
Deviation 
F value p value 
100-149 22 0.891 0.3194 
17.420 <0.001 
150-199 34 1.525 0.5547 
200-249 18 1.611 0.4256 
>= 250 26 1.922 0.5849 
 
TABLE 17: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO POST PRANDIAL BLOOD 
SUGAR VALUES AND CORRELATION WITH CIMT 
The mean Post prandial Blood Sugar in total study group was 203± 61.6 mg% 
In the study population, 22 people had postprandial blood sugar values between 
100mg% and 149 mg% and the mean CIMT was 0.891±0.3194mm. 
In the study population, 34 people had postprandial blood sugar values between 
150mg% and 199 mg% and the mean CIMT was 1.525±0.5547mm 
In the study population, 18 people had postprandial blood sugar values between 
200 mg% and 249 mg% and the mean CIMT was 1.611±0.4256mm. 
In the study population, 26 people had postprandial blood sugar values more 
than 250mg% and the mean CIMT was 1.922±0.5849mm 
The postprandial blood sugar values showed a positive correlation with 
CIMT values which was statistically significant. (p value < 0.001) 
 Figure 32: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO POSTPRANDIAL BLOOD SUGAR VALUES 
 
 
Figure 33: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO POSTPRANDIAL BLOOD SUGAR VALUES AND 
CORRELATION WITH CIMT 
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18.  DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO  
HbA1c LEVELS AND CORRELATION WITH CIMT 
 
 
HbA1c No. 
Mean 
CIMT 
Std 
deviation 
F value p value 
6.1-7 37 1.175 0.5629 
15.458 <0.001 7.1-8 40 1.545 0.5283 
> 8 23 1.963 0.5105 
 
TABLE 18: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO HbA1c LEVELS AND 
CORRELATION WITH CIMT 
The mean HbA1c of the total study group was 7.461± 0.786 
In the study population, 37 people had HbA1c between 6.1and 7 and the mean 
CIMT was 1.175±0.5629mm. 
In the study population, 40 people had HbA1c between 7.1 and 8 mg% and the 
mean CIMT was 1.545±0.5283mm 
In the study population, 23 people had HbA1c more than 8 and the mean CIMT 
was 1.963±0.5105mm 
The HbA1c values showed a positive correlation with CIMT values which 
was statistically significant. (p value < 0.001) 
 Figure 34: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO  HbA1c LEVELS 
 
 
Figure 35: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO  HbA1c LEVELS AND CORRELATION WITH CIMT 
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19.  DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
HYPEGLYCEMIA AND CORRELATION WITH CIMT 
Hyperglycemia No. Mean CIMT (mm) Std. Deviation p value 
Yes 43 1.809 0.5412 
<0.001 
No 57 1.275 0.5618 
TABLE 19.DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO HYPERGLYCEMIA AND 
CORRELATION WITH CIMT 
In the study population, 43 people had hyperglycemia (FBS> 100 mg% and 
PPBS> 200 mg %) and the mean CIMT was 1.809±0.5412mm. 
In the study population, 57 people had no hyperglycemia (FBS> 100 mg% and 
PPBS> 200 mg %) and the mean CIMT was 1.275±0.5618mm 
The hyperglycemic group had a higher mean CIMT value compared to the 
non hyperglycemic group and the difference was statistically significant.(p 
value <0.001) 
  
 
Figure 36: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO HYPEGLYCEMIA 
 
 
Figure 37: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO HYPEGLYCEMIA AND CORRELATION WITH CIMT 
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20. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO  
HYPERTRIGLYCERIDEMIA AND CORRELATION WITH CIMT 
Hypertriglyceridemia No. Mean CIMT (mm) Std. Deviation p value 
Yes 37 1.964 0.4196 
<0.001 
No 63 1.235 0.5421 
 
TABLE 20.DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO HYPERTRIGLYCERIDEMIA AND 
CORRELATION WITH CIMT 
In the study population, 37 people had hypertriglyceridemia (FTG> 150 mg% 
and PPTG> 200 mg %) and the mean CIMT was 1.964±0.4196mm. 
In the study population, 63 people had no hypertriglyceridemia (FTG> 150 
mg% and PPTG> 200 mg %) and the mean CIMT was 1.235±0.5421mm 
The hypertriglyceridemic group had a higher mean CIMT value compared 
to the non hypertriglyceridemic group and the difference was statistically 
significant. (p value <0.001) 
 
  
Figure 38: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO  HYPERTRIGLYCERIDEMIA 
 
Figure 39: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO  HYPERTRIGLYCERIDEMIA AND CORRELATION 
WITH CIMT 
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21. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO  
HYPERGLYCEMIA AS WELL AS HYPERTRIGLYCERIDEMIA AND 
CORRELATION WITH CIMT 
Hyperglycemia and 
Hypertriglyceridemia 
No. 
Mean 
CIMT(mm) 
Std. 
Deviation 
p value 
Yes 22 2.092 0.3728 
<0.001 
No 78 1.339 0.5617 
 
TABLE 21.DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO HYPERGLYCEMIA AS WELL AS 
HYPERTRIGLYCERIDEMIA AND CORRELATION WITH CIMT 
 
In the study population, 22 people had hyperglycemia (FBS> 100 mg% and 
PPBS> 200 mg %) as well as hypertriglyceridemia (FTG> 150 mg% and 
PPTG> 200 mg %) and the mean CIMT was 2.092±0.3728mm. 
In the study population, 78 people had no hyperglycemia (FBS> 100 mg% and 
PPBS> 200 mg %) as well as no hypertriglyceridemia (FTG> 150 mg% and 
PPTG> 200 mg %) and the mean CIMT was 1.339±0.5617mm. 
The group with hyperglycemia as well as hypertriglyceridemia had a 
higher mean CIMT value compared to the normal group and the difference 
was statistically significant.(p value <0.001) 
 Figure 40: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO HYPERGLYCEMIA AS WELL AS 
HYPERTRIGLYCERIDEMIA  
 
 
Figure 41: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO HYPERGLYCEMIA AS WELL AS 
HYPERTRIGLYCERIDEMIA AND CORRELATION WITH CIMT 
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22. DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO  
POST PRANDIAL HYPERGLYCEMIA AS WELL AS POST PRANDIAL 
HYPERTRIGLYCERIDEMIA AND CORRELATION WITH CIMT 
 
 
TABLE 22: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO POST PRANDIAL 
HYPERGLYCEMIA AS WELL AS POST PRANDIAL HYPERTRIGLYCERIDEMIA AND CORRELATION WITH 
CIMT 
 
In the study population, 32 people had post prandial hyperglycemia  
(PPBS > 200 mg %) as well as post prandial hypertriglyceridemia                        
(PPTG > 200 mg%) and the mean CIMT was 2.014±0.3904mm. 
In the study population, 68 people had no post prandial hyperglycemia     
(PPBS> 200 mg %) or post prandial hypertriglyceridemia (PPTG > 200 mg %) 
and the mean CIMT was 1.265±0.5467mm. 
The group with post prandial hyperglycemia as well as post prandial 
hypertriglyceridemia had a higher mean CIMT value compared to the 
normal group and the difference was statistically significant.(p value 
<0.001) 
 
Post Prandial 
Dysmetabolism No. 
Mean 
CIMT(mm) 
Std. 
Deviation p value 
Yes 32 2.014 0.3904 
<0.001 
No 68 1.265 0.5467 
 Figure 42: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO  POST PRANDIAL HYPERGLYCEMIA AS WELL AS 
POST PRANDIAL HYPERTRIGLYCERIDEMIA 
 
Figure 43: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO  POST PRANDIAL HYPERGLYCEMIA AS WELL AS 
POST PRANDIAL HYPERTRIGLYCERIDEMIA AND CORRELATION WITH CIMT 
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23.  DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
CIMT 
CIMT categories(mm) No. 
< 1.0 32 
1.1-1.5 19 
1.6-2.0 24 
2.1-2.5 21 
2.6-3.0 4 
 
The mean CIMT in the study population was 1.5±0.61mm 
In the study population, 32 people had CIMT values less than 1mm, 19 people 
had CIMT values between 1.1 and 1.5, 24 people had CIMT values between 1.6 
and 2mm, 21 people had values between 2.1 and 2.5mm and only 4 people had 
CIMT values between 2.6 and 3mm. 
 
 Figure 44: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO CIMT 
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24. UNIVARIATE LINEAR REGRESSION 
 
Dependent 
variable 
Independent 
variable 
R
2
 p value 
CIMT PPTG 0.621 <0.001 
CIMT FBS 0.737 <0.001 
CIMT PPTC 0.755 <0.001 
CIMT HbA1c 0.772 <0.001 
 
A stepwise method of regression was done. The three earlier significant 
variables PPBS, FTC and FTG were excluded in the first step. This shows that 
even though the PPBS, FTC and FTG values were correlating with the CIMT, 
they did not exert a significant influence in the CIMT values when other 
significant parameters were adjusted for. 
Four parameters were found to influenze the CIMT values in a statistically 
significant manner ie.PPTG, FBS, PPTC and HbA1c. 
The model R
2 
(coefficient of determination)
 
for PPTG alone was 0.621 which 
along with p value of <0.001 showed that about 62% of the variation in CIMT 
can be explained by postprandial triglyceride levels. 
When the other significant parameters were added on, the model R
2 
 for 
FBS,PPTC and HbA1c were  0.737,0.755 and 0.772 respectively all with a p 
value of <0.001 showing that all these values contributed to the variation in the 
CIMT values in a significant manner. 
25. MULTIVARIATE LINEAR REGRESSION CORRELATION WITH 
CIMT 
 
Variables B T p value 
PPTG 0.003 7.290 <0.001 
FBS 0.005 3.899 <0.001 
PPTC 0.002 2.820 0.006 
HbA1c 0.113 2.649 0.009 
 
The above table shows a multivariate linear regression model when all the 
significant parameters were correlated with CIMT. The overall R
2 
(coefficient 
of determination) was 0.772 which was higher compared to the univariate linear 
regression including only PPTG (0.621). The p values for PPTG and FBS were 
strongly significant i.e. less than 0.001. The p values for PPTC and HbA1c were 
also significant. (p value<0.05) . The R
2 
(coefficient of determination) also 
progressively increased in the stepwise regression analysis showing that the 
above parameters independently and cumulatively influenced the CIMT values. 
 
 
 
 
 
 
 
DISCUSSION 
AGE: 
The Mean Age of the total study group was 48± 7.2 years 
   Khamseh ME et al
(90)
 :-The mean Age group in their study on the evaluation 
of The Association of Carotid Intima-Media Thickness and Postprandial 
Dyslipidemia in Patients with Type 2 Diabetes done in 2007 was 52.9±9.3 
years. 
LIPID PROFILE 
FASTING TOTAL CHOLESTEROL: 
 The mean Fasting Total Cholesterol of the total study group was 166± 38.2 
mg% 
Khamseh ME et al :-  
In their study, the mean Fasting Total Cholesterol of the total study group was 
180.2±33.4 mg% 
POST PRANDIAL TOTAL CHOLESTEROL: The mean Post Prandial 
Total Cholesterol of the total study group was 246± 53.1 mg% 
Khamseh ME et al :- 
 In their study, the mean Post Prandial  Total Cholesterol of the total study 
group was 189.8±46.9 mg% 
FASTING HDL: The mean fasting HDL of the total study group was 33.7 
±5.98mg% 
Khamseh ME et al :- In their study, the mean fasting HDLof the total study 
group was 47.2±10.6 mg% 
POSTPRANDIAL HDL: The mean postprandial HDL of the total study group 
was 34.9± 6.72 mg% 
Khamseh ME et al :- In their study, the mean postprandial HDL of the total 
study group was 47±18.6mg% 
FASTING LDL: The mean fasting LDL of the total study group was 93.9±26.9 
mg% 
Khamseh ME et al :- In their study, mean fasting LDL of the total study group 
was 100.8±22.5 mg% 
POSTPRANDIAL LDL: The mean post prandial LDL of the total study group 
was 128.5±35.08mg% 
Khamseh ME et al :-In their study, the The mean post prandial LDL of the 
total study group was 103±32.2 mg% 
 
 
FASTING TRIGLYCERIDES: The mean Fasting triglycerides of the total 
study group was 156±60.2 mg% 
Khamseh ME et al :- In their study, the mean Fasting triglycerides of the total 
study group was 146.1±63.5 mg% 
POSTPRANDIAL TRIGLYCERIDES: The mean Post prandial Triglycerides 
of the total study group was 235± 9.9 mg% 
Khamseh ME et al :- In their study, the mean Post prandial Triglycerides of 
the total study group was 194±106.4 mg% 
HYPERGLYCEMIA 
FASTING BLOOD SUGAR: The mean Fasting Blood Sugar of the total study 
group was 122± 35.1 mg% 
Khamseh ME et al :- In their study, the mean Fasting Blood Sugar of the total 
study group was 167.2±45.2 mg% 
The KORA F4 Study
(91)
:-In their study, the mean Fasting Blood Sugar of the 
total study group was 142.34±36.03mg% 
 
 
POSTPRANDIAL BLOOD SUGAR: The mean Post prandial Blood Sugar  in 
total study group was 203± 61.6 mg% 
Khamseh ME et al :- In their study, the mean Post prandial Blood Sugar  in 
total study group was 194.5±69.1 mg% 
HbA1c: The mean HbA1c of the total study group was 7.461± 0.786 
The KORA F4 Study:- 
       In the KORA F4 study done to analyse Associations 
between Blood Glucose and Carotid Intima- Media Thickness in Diabetic 
population, the mean HbA1C was 6.9 ± 1.1 . The mean CIMT in the diabetic 
group was 0.94±0.13mm. 
 
 
RELATED STUDIES AND CONCLUSIONS 
 
1.Khamseh et al:- 
 
The study done in 2007 supports the association of fasting hyperglycemia          
and postprandial hypertriglyceridemia with carotid intima media thickness in 
patients with type 2 diabetes. 
2.Snichi Teno et al
(92)
:- 
This elegant study done by Teno et al in 2000.The chief observations in the 
study were that Carotid Intima Media Thickness was increased in patients with 
postprandial hypertriglyceridemia despite normal fasting triglyceride  levels, 
and the postprandial triglyceride levels showed the strongest influence on 
carotid IMT(p value=0.002, R
2 
=0.414). 
 
 
3.Friedrick Karpe etal 
(17)
:- 
In this study,the magnitude of alimentary lipemia was correlation with Carotid 
Intima Media Thickness in middle aged men. The postprandial triglycerdies, 
especially those measured 3-6 hours after intake of test meal, showed positive 
correlation with CIMT values(p<0.05). 
 
4. V. Mohan et al
(89)
:- 
In this study, the CIMT in South Indian population was found to be significantly 
higher in the diabetic group compared to the non diabetic group(0.95±0.31 in 
diabetic group versus 0.74±0.14 with p value<0.001). 
5. KORA F4 study:- 
In this study, PPBS and HbA1c were not significantly associated with CIMT 
after adjustment for age and sex. FPG was significantly associated with CIMT 
after adjustment for age, sex, and hypertension. In a fully adjusted logistic 
regression model, age, sex, hypertension, waist circumference, HDL and LDL 
cholesterol were all independently associated with elevated CIMT whereas the 
association was significant neither for HbA1c nor for FBS nor for PPBS 
.6. Sainani et al 
(93)
:-Post prandial hyperglycemia is directly responsible for 
increase in C-IMT and as the level of post prandial blood sugar increases there 
is proportionate increase in the IMT.  With increasing age there is proportionate 
increase in IMT in patients with post prandial hyperglycemia ascompared to 
those without post prandial hyperglycemia. 
7. Luca Saba et al
(94)
:-  
The study concluded that the automated CIMT values and the levels of HbA1c 
are correlated whereas the plaque score does not show any statistically 
significant correlation. 
8.Yoshimitsu et al
(95)
:- 
In the study, HbA1c showed a weak but significant association with the 
progression of IMT, which has been shown to be associated with the incidence 
of CHD 
 
RELATIONSHIP OF THE VARIABLES WITH CIMT: 
Age, duration since diagnosis, sex, mode of treatment, history of smoking, 
history of alcohol intake, BMI, history of systemic hypertension, the 
systolic and diastolic blood pressure values, both fasting and postprandial 
HDL, both fasting and postprandial LDL. 
The p value for the above parameters was not significant as noted earlier 
suggesting that all these variables did not influence the CIMT in a significant 
manner. 
  
The fasting and postprandial cholesterol, fasting and post prandial 
triglycerides, fasting and post prandial blood sugar values, the HbA1c 
values all correlated significantly with the CIMT values(p value<0.001) 
showing the influence of these parameters to the variation in CIMT and hence 
their atherogenic potential. 
Among the significant parameters, the postprandial Cholesterol, postprandial 
Triglycerides, fasting blood sugar and HbA1c were found to be significant in 
both univariate and multivariate regression analysis. Among these post prandial 
triglyceride level had the strongest influence on the CIMT values. 
LIMITATIONS OF THE STUDY 
The study population consisted of only 100 people. Increasing the study 
population would have provided more insight into the correlations. The CIMT 
measurements were also subject to observer variation. The test meals were 
standardized to maximum extent possible but absolute standardization was not 
possible. 
 
 
 
  
CONCLUSION 
1. The Carotid intima media thickness is significantly increased in people 
with postprandial dyslipidemia (especially postprandial 
hypertriglyceridemia and postprandial hypercholesterolemia).Among the 
dyslipidemias,  postprandial triglycerides exert the strongest influence on 
the variation in the Carotid intima media thickness. 
2. The HbA1c levels also independently influence the Carotid intima media 
thickness. 
3. Chronic hyperglycemia and postprandial dyslipidemia both independently 
and cumulatively influence the Carotid intima media thickness. 
4. Chronic hyperglycemia and postprandial dyslipidemia can be labeled as 
independent predictor of accelerated atherosclerosis in individuals with 
type 2 Diabetes Mellitus. 
5. In diabetic individuals, postprandial lipid profile may be suggested to 
predict the future macrovascular complication of diabetes mellitus. 
6.  Hence suggested emphasis on post prandial lipid profile estimation in all 
diabetic individuals. 
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ABBREVIATIONS 
 
ACAT = Acetyl-Coenzyme A acetyltransferase 
ACCORD = Action to Control Cardiovascular Risk in Diabetes 
ACE = angiotensin-converting-enzyme inhibitor 
 
AGE =Advanced glycation end-product 
 
Apo = Apolipoprotein 
AT II = Angiotensin two 
ATP =  Adenosine triphosphate 
CAD = Coronary artery disease 
CETP =  Cholesteryl ester transfer protein 
CIMT =  Carotid intima-media thickness 
DCCT = Diabetes Control and Complications Trial 
DECODE = Diabetes Epidemiology: Collaborative analysis of Diagnostic 
criteria in Europe 
DM = Diabetes Mellitus 
DNA = Deoxyribonucleic acid 
FAD =  flavin adenine dinucleotide 
FGF = Fibroblast growth factors 
FMD =  flow-mediated dilatation 
GH = Growth hormone 
HbA1c = glycated Haemoglobin A1c 
HDL = High-density lipoprotein 
ICAM = Intercellular Adhesion Molecule 
IDL = Intermediate-density lipoproteins 
IGF = Insulin-like growth factor 
IHD = ischemic heart disease 
LCAT = Lecithin cholesterol acyltransferase deficiency  
LDL = Low-density lipoprotein  
LpL = lipoprotein lipase 
LRC = Lipid Research Clinics 
MRFIT =  Multiple Risk Factor Intervention Trial 
NADH = Nicotinamide adenine dinucleotide 
NOS =  nitric oxide synthase 
PAI = Plasminogen activator inhibitor 
PDGF = platelet-derived growth factor 
PKC = Protein kinase C 
PUFA = Polyunsaturated fatty acids 
ROS = Reactive oxygen species 
SPSS = Statistical Product and Service Solutions 
STEMI = ST segment elevation myocardial infarction 
TG = Triglycerides 
TGF = Transforming growth factor 
TRL = Triglyceride-rich lipoproteins 
UKPDS =  UK Prospective Diabetes Study 
VCAM = vascular cell adhesion molecule 
VLDL =  Very-low-density lipoprotein 
vWF =  Von Willebrand factor 
QUESTIONNAIRE PROFORMA 
ASSOCIATION OF POSTPRANDIAL DYSLIPIDEMIA AND HBA1c LEVELS  WITH 
CAROTID INTIMA-MEDIA THICKNESS IN PATIENTS WITH TYPE 2 DIABETES 
MELLITUS 
 
NAME: 
AGE: 
SEX: 
ADDRESS: 
TELEPHONE NUMBER: 
OCCUPATION: 
DURATION OF DIABETES MELLITUS: 
DRUG HISTORY: 
Insulin/OHA 
Lipid lowering agents 
Thiazides 
Beta blockers 
Thyroxine 
ACE inhibitors 
AT II antagonists 
Antiplatelets 
 
PERSONAL HISTORY: 
Alcoholism 
Smoker  
HISTORY:  h/o of chest pain 
h/o of previous IHD 
h/o systemic hypertension 
h/o  CKD 
h/o of CVA 
h/o dimness of vision 
h/o hypothyroidism 
h/o eye surgeries 
h/o  surgeries 
h/o alcohol consumption /drinking pattern 
h/o smoking (in pack years) 
h/o jaundice, acsites 
 
 
 
 
 
 
 
 
 
 
 
EXAMINATION 
 
 
HEIGHT: 
WEIGHT: 
BMI: 
PULSE RATE: 
 
PERIPHERAL PULSES EXAMINATION: 
 
BLOOD PRESSURE:                           
RECORDINGS  READING 
SITTING  
SUPINE  
 
GENERAL EXAMINATION: 
 
 
SYSTEMWISE EXAMINATION: 
CVS: 
RS: 
P/A: 
CNS: 
 
 
INVESTIGATIONS 
Complete blood count: 
Hb: 
ESR: 
TC: 
DC: 
Chest Xray: 
Blood Urea: 
Serum Creatinine: 
Urine Albumin: 
a. Sugar: 
 
b. Microscopy: 
 
Serum Bilirubin: 
ALT/AST: 
ALP:  
 
TEST REPORT 
1.FASTING PLASMA GLUCOSE (mg/dl) 
 
 
 
2.POST PRANDIAL PLASMA 
GLUCOSE(mg/dl) 
 
 
3.HBA1c  
4.FASTING TRIGLYCERIDES (mg/dl) 
 
  
 
TEST REPORT 
5.POSTPRANDIAL TRIGLYCERIDES 
(mg/dl) 
 
 
6.FASTING TOTAL CHOLESTEROL 
(mg/dl) 
 
 
7.POSTPRANDIAL TOTAL 
CHOLESTEROL (mg/dl) 
 
8.FASTING LDL  
9.POST PRANDIAL LDL  
10. FASTING HDL  
11. POST PRANDIAL HDL  
12.ECG  
 
 
13.ECHO  
 
 
 
 
 
14.CIMT  
 
 
 
 
 
 
 CAROTID DOPPLER: 
 
CIMT:  
Right:       Left: 
 RIGHT SIDE LEFT SIDE 
 S mm S/D mm P/I mm S mm S/D mm P/I mm 
CCA       
ECA       
ICA       
Master Chart 
Sl.# age sex DUR oha/insu smoking alcohol weight Height BMI shtn SBP DBP FBS PPBS FTC PPTC FHDL PPHDL FLDL PPLDL VLDL FTG PPTG HbA1c CIMT 
1 48 M 2 O Y Y 84 172 28.4 N 120 70 108 176 198 272 42 45 68 72 24 115 163 6.4 1.1 
2 36 M 1 O Y Y 73 157 29.6 N 120 70 116 185 266 298 28 29 108 113 32 139 282 7 2.3 
3 37 M 2 O N Y 74 165 27.2 N 110 68 134 213 178 242 26 28 78 84 30 140 260 7.3 2.2 
4 42 F 2 O N N 58 149 26.1 N 100 60 121 157 231 348 29 24 127 134 42 178 275 6.9 2.55 
5 52 M 3 O N N 67 157 27.2 N 110 70 98 146 147 219 42 48 53 59 18 95 154 6.5 0.88 
6 47 M 5 O N N 87 168 30.8 N 130 70 89 126 162 220 36 32 74 77 17 123 176 6.2 1.53 
7 56 M 4 O Y N 92 172 31.1 N 120 70 117 182 296 364 22 26 122 130 54 200 354 6.9 2.27 
8 41 M 2 O N N 88 170 30.4 N 130 90 154 244 274 320 30 27 105 108 57 189 274 8.3 2.12 
9 47 M 2 O N Y 89 170 30.8 N 140 80 124 188 193 277 37 39 99 110 34 140 218 7.6 1.3 
10 57 M 3 O N Y 92 180 28.4 N 110 70 96 142 102 165 36 37 63 72 17 89 139 6.4 0.97 
11 58 M 4 I N Y 76 168 26.9 N 112 68 126 249 179 256 48 51 89 93 47 235 307 7.8 2.12 
12 47 F 1 O N N 69 156 28.4 Y 150 90 112 198 222 273 35 37 150 152 43 190 206 6.76 1.19 
13 54 F 2 I Y N 68 153 29.0 N 100 70 145 279 156 209 35 39 64 69 79 297 312 7.6 1.83 
14 39 M 2 O N Y 78 172 26.4 N 110 70 165 296 256 389 39 42 150 160 46 210 406 8.2 2.32 
15 49 F 4 O N N 88 163 33.1 N 120 74 170 306 180 235 39 38 92 99 57 260 325 7.99 1.92 
16 42 F 2 O N N 67 157 27.2 N 120 70 86 112 124 196 37 42 73 81 28 100 129 6 0.61 
17 52 M 2 I Y N 98 179 30.6 Y 150 86 182 256 125 180 33 30 74 79 26 139 248 8.6 2.12 
18 40 M 2 O N N 80 168 28.3 Y 140 90 113 274 130 203 29 27 86 100 20 92 104 8.6 1.4 
19 36 F 1 O N N 60 158 24.0 Y 150 100 140 216 167 345 24 29 92 103 59 270 290 7.2 1.9 
20 51 M 3 I Y Y 82 174 27.1 Y 130 80 196 328 173 276 31 28 110 124 46 173 329 8.7 2.79 
21 43 M 2 O Y Y 69 168 24.4 Y 140 90 112 256 129 198 27 25 78 84 27 123 139 8 0.98 
22 52 M 1 O N Y 65 162 24.8 N 120 80 120 176 126 211 30 26 87 97 19 81 102 6.45 1.19 
23 56 M 2 I N N 70 165 25.7 N 136 80 162 198 169 284 27 24 100 118 58 263 342 6.8 1.9 
24 41 F 2 O N N 56 152 24.2 N 110 70 86 100 140 265 40 41 74 79 23 124 192 6.3 0.8 
25 44 M 3 O Y Y 82 169 28.7 N 134 80 147 195 143 269 30 34 87 94 27 140 283 7 2.44 
Master Chart 
 
Sl.# age sex DUR oha/insu smoking alcohol weight Height BMI shtn SBP DBP FBS PPBS FTC PPTC FHDL PPHDL FLDL PPLDL VLDL FTG PPTG HbA1c CIMT 
26 43 F 5 O N N 42 160 16.4 Y 140 96 68 143 162 287 40 39 110 115 19 86 140 6.45 0.68 
27 42 M 4 O Y Y 80 170 27.7 Y 132 70 130 219 189 322 35 34 116 125 39 182 293 7.8 1.48 
28 47 F 2 O N N 64 156 26.3 N 110 72 126 200 143 263 30 36 72 75 28 140 212 7.6 1.18 
29 53 M 2 I N Y 79 182 23.8 N 120 72 140 224 118 180 35 32 63 76 27 131 223 8.1 1.6 
30 38 M 3 O N N 80 173 26.7 N 132 70 90 170 163 290 32 29 109 126 18 80 130 6.46 0.61 
31 59 M 4 O N Y 67 170 23.2 N 124 68 172 283 140 239 29 27 93 102 26 123 290 8.6 2.33 
32 60 M 1 O Y N 87 173 29.1 N 140 90 145 236 160 262 43 42 94 99 26 147 236 9 1.74 
33 57 F 2 I N N 60 158 24.0 N 130 90 100 279 100 169 30 31 53 58 24 118 138 8.2 0.66 
34 40 F 2 O N N 58 149 26.1 Y 120 70 132 265 173 267 40 37 101 113 27 137 256 8.5 2.04 
35 58 F 4 O N N 72 156 29.6 Y 142 90 116 186 193 311 38 39 117 125 37 193 276 6.99 1.47 
36 48 M 2 O Y Y 79 169 27.7 N 110 70 117 248 149 256 28 29 109 119 19 88 136 7.9 0.68 
37 49 F 2 I N N 70 161 27.0 Y 150 110 154 197 136 231 28 27 65 75 27 146 260 6.8 1.73 
38 38 M 2 O N Y 77 170 26.6 Y 146 96 79 117 140 217 35 36 90 98 22 102 130 6.5 0.77 
39 46 F 1 O N N 57 158 22.8 N 110 60 210 281 230 402 36 38 177 189 31 184 306 9.2 2.35 
40 59 M 3 I Y N 69 168 24.4 N 140 60 80 140 190 316 34 32 103 110 59 236 289 6.78 1.39 
41 36 M 2 O N N 67 165 24.6 N 110 70 123 259 153 180 29 28 100 118 26 135 179 8.8 1.32 
42 42 M 1 O N Y 80 170 27.7 N 110 70 143 280 174 216 40 41 101 112 30 140 185 8.3 2.1 
43 46 M 3 O N N 76 172 25.7 N 120 70 190 342 150 276 22 26 97 108 22 146 197 9.2 1.97 
44 39 M 2 O N Y 79 183 23.6 N 100 70 119 164 164 304 20 23 112 120 20 189 273 6.3 1.69 
45 47 F 1 O N N 72 161 27.8 N 130 80 127 265 198 294 32 29 126 140 32 194 309 8.7 2.14 
46 52 M 2 O N N 82 176 26.5 Y 140 90 95 123 168 297 30 28 124 136 30 169 280 6.7 1.83 
47 56 F 2 O N N 60 157 24.3 Y 150 90 87 106 126 187 54 56 56 62 54 112 164 6.5 0.77 
48 46 M 3 O N N 63 176 20.3 N 124 96 116 186 102 167 37 36 63 70 16 86 139 7 0.95 
49 54 F 5 O N N 72 157 29.2 Y 126 70 121 224 162 189 40 36 107 145 15 73 190 7.7 1.4 
50 35 F 4 O N N 59 162 22.5 N 130 80 109 232 112 200 30 32 59 156 30 121 200 8 1.6 
Master Chart 
 
Sl.# age sex DUR oha/insu smoking alcohol weight Height BMI shtn SBP DBP FBS PPBS FTC PPTC FHDL PPHDL FLDL PPLDL VLDL FTG PPTG HbA1c CIMT 
51 50 M 2 O N Y 92 179 28.7 N 110 60 89 123 166 178 36 39 104 113 22 106 136 6.7 0.76 
52 62 M 2 O N Y 62 164 23.1 Y 130 80 90 145 130 190 30 27 79 97 23 122 130 7.2 0.88 
53 55 F 3 I N N 52 157 21.1 Y 140 80 102 179 175 230 41 34 89 103 43 232 304 7 1.23 
54 48 M 4 O Y Y 63 162 24.0 N 130 70 145 190 146 270 28 30 87 178 27 131 292 7.4 2.34 
55 60 F 1 O N N 74 154 31.2 N 110 80 138 168 162 245 32 31 104 137 30 147 172 7.2 1.4 
56 43 M 2 O Y Y 69 166 25.0 N 128 90 168 280 196 230 37 35 92 165 40 196 290 8.1 1.72 
57 58 M 2 O Y N 57 159 22.5 N 116 70 211 298 134 290 22 26 51 170 59 330 402 8 2.79 
58 54 M 4 I N N 92 152 39.8 Y 140 90 114 170 166 278 36 37 96 180 32 168 236 7.2 1.72 
59 52 F 2 I N N 59 148 26.9 N 120 70 80 200 150 178 31 26 107 143 25 110 156 6.8 1.2 
60 56 F 2 I N N 60 158 24.0 Y 150 110 69 121 151 170 30 37 103 123 18 87 103 6.6 0.62 
61 59 M 2 O Y Y 57 156 23.4 N 110 70 135 196 172 199 40 35 77 170 50 269 532 7.6 2.42 
62 41 M 2 O N Y 60 164 22.3 N 130 70 79 199 126 300 32 32 74 166 23 128 232 7.8 1.9 
63 56 F 3 O N N 69 161 26.6 N 120 70 110 214 220 347 31 38 146 176 41 187 233 8 1.8 
64 40 F 4 I N N 83 156 34.1 N 130 80 103 156 152 220 35 36 93 145 24 134 173 7.1 0.99 
65 45 F 1 O N N 69 160 27.0 Y 100 70 245 319 156 280 32 38 64 154 80 300 510 7.9 2.33 
66 40 M 2 O Y Y 62 152 26.8 Y 130 86 90 165 167 210 43 41 90 124 28 136 189 6.4 0.85 
67 47 M 2 O Y N 70 170 24.2 N 120 78 135 178 242 276 32 36 180 156 43 220 307 7.6 2.2 
68 37 M 2 O Y Y 70 176 22.6 N 110 80 97 149 141 198 36 37 80 123 28 122 190 7.2 0.9 
69 39 F 1 O N N 62 158 24.8 Y 134 80 87 164 154 178 37 34 88 125 20 99 125 6.8 0.72 
70 40 F 2 O N N 56 162 21.3 N 126 74 127 206 163 269 35 38 93 176 33 169 240 7.6 1.64 
71 43 M 3 O Y Y 72 160 28.1 N 130 70 139 284 100 230 28 27 60 136 24 99 178 8.2 0.94 
72 43 M 4 O Y N 80 170 27.7 N 120 70 148 235 187 289 46 50 83 187 54 266 513 7.9 2.13 
73 44 M 3 I N Y 84 168 29.8 N 130 80 129 190 145 260 29 30 87 168 28 137 299 8.4 1.96 
74 49 F 1 O N N 56 148 25.6 N 100 60 89 168 198 320 34 37 104 160 55 282 385 7.4 1.44 
75 50 F 2 O N N 58 156 23.8 Y 140 100 96 152 197 300 36 39 120 154 30 149 219 7.7 1.3 
Master Chart 
 
Sl.# age sex DUR oha/insu smoking alcohol weight Height BMI shtn SBP DBP FBS PPBS FTC PPTC FHDL PPHDL FLDL PPLDL VLDL FTG PPTG HbA1c CIMT 
76 58 F 4 I N N 65 150 28.9 Y 126 86 84 99 156 178 38 40 110 149 23 113 126 7.8 0.66 
77 52 F 3 O N N 66 158 26.4 N 130 80 90 118 178 204 36 39 108 139 23 108 195 6.5 0.7 
78 52 M 3 O Y Y 76 169 26.6 N 128 70 102 170 195 230 29 28 113 143 27 135 170 7.2 0.94 
79 55 M 2 O N Y 90 172 30.4 Y 150 96 100 140 120 178 37 35 103 130 18 86 134 6.6 0.66 
80 56 F 5 O N N 63 157 25.6 N 140 90 76 112 158 190 39 43 74 142 26 101 140 7.2 0.88 
81 57 M 3 O N N 69 169 24.2 Y 144 90 125 169 176 269 19 27 57 174 34 169 230 7.8 1.53 
82 48 M 6 O N Y 77 174 25.4 Y 160 90 109 208 119 200 39 43 93 178 39 194 290 7.6 1.64 
83 50 M 4 O N Y 82 170 28.4 N 120 78 100 132 140 190 32 38 56 145 25 100 136 6.8 0.74 
84 52 F 3 O N N 60 162 22.9 N 110 70 107 155 200 260 36 38 76 150 24 126 145 7.1 0.96 
85 48 M 1 I N N 72 160 28.1 N 126 86 179 270 246 300 36 40 127 167 37 198 295 9.2 2.32 
86 58 M 3 O N Y 80 176 25.8 Y 130 90 209 315 187 260 31 38 187 204 42 196 308 8.9 2.44 
87 45 M 4 O Y Y 69 162 26.3 N 130 70 120 136 190 260 39 45 74 156 28 145 216 6.6 1.2 
88 38 F 4 O N N 56 154 23.6 N 150 90 79 187 146 190 40 54 99 159 28 279 430 7.3 1.8 
89 37 M 2 O N N 70 171 23.9 Y 130 96 90 169 120 196 35 39 62 185 27 128 230 7.2 1.56 
90 38 F 4 O N N 53 156 21.8 N 130 80 138 257 200 230 28 37 60 169 25 232 303 8.3 1.98 
91 42 F 4 O N N 60 152 26.0 Y 110 78 98 148 156 220 28 30 110 140 19 89 130 7 0.65 
92 45 M 3 O Y N 78 167 28.0 N 128 84 100 160 170 198 32 35 106 136 19 86 129 6.8 0.8 
93 46 M 5 I N N 70 172 23.7 N 130 80 102 174 176 204 36 35 78 99 28 136 176 7.4 1.11 
94 48 M 4 O N Y 89 177 28.4 Y 120 70 156 378 143 238 28 30 94 176 27 129 297 8.3 2.2 
95 50 M 5 I N Y 94 182 28.4 N 110 70 116 267 169 220 29 30 114 138 25 118 190 6.9 0.99 
96 52 F 4 I N N 52 146 24.4 N 120 70 128 230 198 270 44 42 96 176 26 150 245 7.4 1.67 
97 54 M 3 O N N 68 168 24.1 N 130 70 70 140 121 190 35 39 56 134 27 119 160 7 0.73 
98 56 M 3 O N N 78 170 27.0 N 120 60 132 290 164 297 37 40 64 148 64 309 380 8.8 2.6 
99 59 M 5 O N Y 82 174 27.1 Y 150 90 126 258 189 245 28 27 117 167 29 128 320 7.8 1.4 
100 55 F 2 O N N 54 150 24.0 N 110 70 108 230 147 189 30 37 87 152 16 89 110 7.2 0.89 
KEYS TO MASTERCHART 
 
DUR = duration since diagnosis of type 2 Diabetes Mellitus (in years) 
O = Oral Hypoglycemic Agents used as mode of Treatment 
I = Insulin used as Mode of Treatment 
N = no 
Y= yes 
BMI = Body Mass Index (kg/m
2) 
Shtn= Systemic Hypertension 
SBP= Systolic Blood Pressure( in mm of Hg) 
DBP= Diastolic Blood Pressure (in mm of Hg) 
FBS= Fasting Blood sugar (mg%) 
PPBS= Post Prandial Blood Sugar(mg%) 
 
FTC=Fasting Total Cholesterol (mg%) 
 
PPTC= Post Prandial Total Cholesterol (mg%) 
 
FLDL= Fasting LDL Cholesterol(mg%) 
 
PPLDL= Post Prandial LDL Cholesterol(mg%) 
 
FHDL= Fasting HDL Cholesterol(mg%) 
 
PPHDL= Post Prandial HDL Cholesterol(mg%) 
 
FTG= Fasting Triglycerides (mg%) 
 
PPTG= Post Prandial Triglycerides(mg%) 
 
CIMT= Carotid Intima Media Thickness(mm) 
 
  
